Document:

Exhibit 4.96

 

CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDER AGREEMENT

 

 

 

Dated as of May 11, 2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

TABLE OF CONTENTS

 

Page

 

	ARTICLE I 

DEFINITIONS
	Section 1.1.   Definitions	1
	Section 1.2.   General Interpretive Principles	5
	ARTICLE II 

GOVERNANCE
	Section 2.1.   Board of Directors	5
	ARTICLE III 

TRANSFER RESTRICTIONS
	Section 3.1.   General Transfer Restrictions	8
	Section 3.2.   Specific Transfer Restrictions	8
	Section 3.3.   Permitted Transfers.	10
	ARTICLE IV
	SHARE OWNERSHIP
	Section 4.1.   Standstill	10
	Section 4.2.   Preemptive Rights	12
	ARTICLE V 

REGISTRATION RIGHTS
	Section 5.1.   Certain Definitions	14
	Section 5.2.   Registration	15
	Section 5.3.   Piggyback Registration.	19
	Section 5.4.   Expenses of Registration	21
	Section 5.5.   Obligations of the Company	21
	Section 5.6.   Indemnification.	23
	Section 5.7.   Information by Holder	25
	Section 5.8.   Transfer of Registration Rights	25
	Section 5.9.   Delay of Registration	26
	Section 5.10.   Termination of Registration Rights	26
	

     

     

    

	 

                                                                                ARTICLE VI 

ADDITIONAL AGREEMENTS OF THE PARTIES

	Section 6.1.   Protective Provisions	26
	Section 6.2.   Right of First Negotiation; Toll Manufacturing Option.	26
	Section 6.3.   Further Assurances	27
	Section 6.4.   Tranche II Funding	27
	ARTICLE VII
	TERMINATION
	Section 7.1.   Termination	29
	ARTICLE VIII 

MISCELLANEOUS
	Section 8.1.   Entire Agreement	29
	Section 8.2.   Specific Performance	29
	Section 8.3.   Governing Law	29
	Section 8.4.   Amendment and Waiver	29
	Section 8.5.   Binding Effect	30
	Section 8.6.   Notices	30
	Section 8.7.   Severability	30
	Section 8.8.   Counterparts	30

 

 

 

 

 

 

 

 

 

    ii 

     

    

 

STOCKHOLDER AGREEMENT

 

This STOCKHOLDER AGREEMENT is made as of May 11, 2017, by and between
Amyris, Inc., a Delaware corporation (“Amyris” or the “Company”), and DSM International B.V.,
a Dutch limited liability company (hereinafter referred to as “DSM”).

 

WHEREAS, DSM and Company have entered into the Securities Purchase
Agreement, dated as of May 8, 2017 (as may be amended from time to time, the “Securities Purchase Agreement”),
pursuant to which, upon the terms and subject to the conditions set forth therein, DSM agreed to purchase (i) 25,000 shares (the
“Shares”) of the Series B preferred stock, par value $0.0001 per share, of the Company (the “Preferred
Stock”), (ii) warrants (the “Cash Warrants”) to acquire up to 59,521,740 shares of the common stock,
$0.0001 per share (the “Common Stock”), of the Company (such shares, the “Cash Warrant Shares”),
and (iii) additional warrants to purchase shares of Common Stock as a result of certain dilutive issuances of equity by the Company
(the “Anti-Dilution Warrants” and, together with the Cash Warrants, the “Warrants,” and the
shares of Common Stock issuable upon exercise of the Anti-Dilution Warrants, the “Anti-Dilution Warrant Shares”
and, together with the Cash Warrant Shares, the “Warrant Shares”); and

 

WHEREAS, DSM and the Company desire to set forth certain rights and
obligations of DSM and the Company with respect to DSM’s investment in the Company.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, the parties mutually agree as follows:

 

ARTICLE
I

DEFINITIONS

 

Section 1.1.                      
Definitions. As used in this Agreement, the following terms shall have the meanings set forth
below:

 

“Adverse Disclosure” means public disclosure of
material non-public information which, in the judgment of the Non-DSM Directors: (i) would be required to be made in any report
or registration statement filed with the SEC by the Company so that such report or registration statement would not be materially
misleading; (ii) would not be required to be made at such time but for the filing, effectiveness or continued use of such report
or registration statement; and (iii) the Company has a bona fide business purpose for not disclosing publicly.

 

“Affiliate” means, with respect to any Person, any
other Person that controls, is controlled by, or is under common control with such Person. The term “control”,
as used with respect to any Person, means the power to direct or cause the direction of the management and policies of such Person,
directly or indirectly, whether through the ownership of voting securities, by contract or otherwise. “Controlled”
and “controlling” have meanings correlative to the foregoing.

 

“Agreement” means this Stockholder Agreement, as
the same may be amended, supplemented, restated or modified.

 

    

     

    

 

“Beneficial Ownership” and “Beneficially
Own” and similar terms have the meaning set forth in Rule 13d-3 under the Exchange Act. For the avoidance of doubt, and
except as otherwise provided herein, DSM will be deemed to Beneficially Own all of the Warrant Shares issuable upon exercise of
the Warrants held by DSM Parent, its Subsidiaries and controlled Affiliates at the time of determination.

 

“Board” means the Board of Directors of the Company.

 

“Brotas 1” means the Company’s first purpose-built,
large-scale production facility located in Brotas, Brazil.

 

“Brotas 2” means the Company’s planned second
purpose-built, large scale production facility adjacent to Brotas 1, for which ground was broken in February 2017.

 

“Business Day” means any day, other than a Saturday,
Sunday or one on which banks are authorized or required by law to be closed in San Francisco, California or Amsterdam, The Netherlands.

 

“Change of Control Transaction” has the meaning
give to such term in the Company’s Certificate of Designation of Preferences, Rights and Limitations of Series B 17.38% Convertible
Preferred Stock.

 

“Closing” has the meaning set forth in the Securities
Purchase Agreement.

 

“Competitor” means those Persons set forth on Exhibit
A attached hereto and their respective Subsidiaries and controlled Affiliates; provided, however, that the Company may, based
on the reasonable determination of the Board, update the Persons set forth on Exhibit A attached hereto not more than once
in any consecutive 12-month period to include any other Persons that compete with any material portion of the Company’s business
as reasonably determined by the Board; provided, further, that (i) the total number of Persons set forth on Exhibit A shall
not exceed seven (7) and (ii) neither DSM Parent nor any of its Subsidiaries or controlled Affiliates may be added to Exhibit
A.

 

“Convertible Securities” means all outstanding securities
exercisable or exchangeable for, or convertible into, Voting Securities, including the Warrants.

 

“DGCL” means the Delaware General Corporation Law.

 

“Disqualification Event” means the “bad actor”
disqualifying events described in Rule 506(d)(1)(i)-(viii) promulgated under the Securities Act.

 

“Disqualified Designee” means any director designee
to whom any Disqualification Event is applicable, except for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or
(d)(3) is applicable.

 

“DSM Director” means the DSM Nominee who is elected
or appointed to the Board.

 

    	2

     

    

 

“DSM Nominee” means the individual that DSM is entitled
to nominate for election to the Board pursuant to Section 2.1(a).

 

“DSM Parent” means Koninklijke DSM N.V., a Dutch
public limited company and the ultimate parent of DSM.

 

“Election Notice” shall have the meaning assigned
to in Section 4.2(b).

 

“Exchange Act” means the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder, as the same may be amended from time to time.

 

“Fair Market Value” means (i) with respect to cash
consideration, the total amount of such cash consideration in United States dollars, (ii) with respect to non-cash consideration
consisting of publicly-traded securities, the average daily closing sales price of such securities for the ten (10) consecutive
trading days ending on the trading day immediately preceding the date the Fair Market Value of such securities is required to be
determined hereunder on the principal national securities exchange on which such securities are listed and admitted to trading,
or, if not listed and admitted to trading on any such exchange, the average of the closing bid and asked prices in the over-the-counter
market and (iii) with respect to non-cash consideration not consisting of publicly-traded securities, such amount as is determined
to be the fair market value of the non-cash consideration as of such date in the good faith determination of the Non-DSM Directors.

 

“Group” shall have the meaning assigned to it in
Section 13(d)(3) of the Exchange Act.

 

“Non-DSM Directors” means the members of the Board
other than the DSM Directors.

 

“Ownership Amount” means, as of the date of the
relevant Election Notice, the sum of (A) the number of Shares (on an as-if-converted-to-Common Stock basis, disregarding for such
purpose any conversion limitations thereon) and shares of Common Stock then held by DSM Parent, its Subsidiaries and controlled
Affiliates, plus (B) the number of Warrant Shares issuable if the Warrants then held by DSM Parent, its Subsidiaries and controlled
Affiliates and that have an exercise price that is greater than the price per Participation Share to be issued in the applicable
Post-Closing Issuance were fully exercised on such date.

 

“Ownership Percentage” means, as of the date of
the relevant Election Notice, a fraction, the numerator of which is the Ownership Amount and the denominator of which is the total
number of outstanding Share Equivalents as of the date of the relevant Election Notice.

 

“Participation Shares” means the number of Voting
Securities or Convertible Securities or any other equity or equity-linked securities (including, for the avoidance of doubt, convertible
debt) proposed to be sold by the Company or one of its Subsidiaries in a Post-Closing Issuance.

 

“Person” means an individual, partnership,
corporation, business trust, joint stock company, trust, unincorporated association, joint venture, limited liability company
or any other entity of whatever nature, and shall include any successor (by merger
or otherwise) of such entity.

 

    	3

     

    

 

“Post-Closing Issuance” shall have the meaning assigned
to it in Section 4.2(a).

 

“Restricted Shares” means the Shares, the Warrants
and the Warrant Shares.

 

“Rule 144” means Rule 144 under the Securities Act.

 

“Rule 506(d) Related Party” shall mean with respect
to any Person any other Person that is a beneficial owner of such first Person’s securities for purposes of Rule 506(d) of
the Securities Act.

 

“SEC” means the United States Securities and Exchange
Commission.

 

“Securities Act” means the Securities Act of 1933,
as amended, and the rules and regulations promulgated thereunder, as the same may be amended from time to time.

 

“Share Equivalents” means all outstanding shares
of the Common Stock, together with all shares of Common Stock issuable upon exercise, conversion or exchange of all outstanding
Convertible Securities (whether or not then exercisable, convertible or exchangeable), including the Warrant Shares, that have
an exercise, conversion or exchange price that is greater than the price per Participation Share to be issued in the applicable
Post-Closing Issuance.

 

“Shares” shall have the meaning assigned to it in
the preamble.

 

“Subsidiary” means, with respect to any party, any
corporation, partnership, trust, limited liability company or other non-corporate business enterprise in which such party (or another
Subsidiary of such party) holds stock or other ownership interests representing (A) more that 50% of the voting power of all outstanding
stock or ownership interests of such entity, (B) the right to receive more than 50% of the net assets of such entity available
for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such entity or
(C) a general or managing partnership interest in such entity.

 

“Tranche II Securities” means any shares of Preferred
Stock, shares of Common Stock issuable upon conversion thereof, warrants to acquire shares of Common Stock and shares of Common
Stock issuable upon exercise thereof, in each case, that are acquired by DSM pursuant to its rights under Section 6.4 of this Agreement.

 

“Transfer” means, directly or indirectly, to sell,
transfer, assign, pledge, encumber, hypothecate or similarly dispose of (by merger, testamentary disposition, operation of law
or otherwise), either voluntarily or involuntarily, or to enter into any contract, option or other arrangement or understanding
with respect to the sale, transfer, assignment, pledge, encumbrance, hypothecation or similar disposition of (by merger, testamentary
disposition, operation of law or otherwise), any Transfer Restricted Shares.

 

    	4

     

    

 

“Transfer Restricted Shares” means any Shares, shares
of Common Stock issued upon conversion of the Shares, Warrants, Warrant Shares or any Tranche II Securities.

 

“Voting Securities” means shares of Common Stock
and any other securities of the Company that are permitted by their terms to vote generally in the election of directors. Except
as otherwise provided herein, references to the number or percentage of Voting Securities outstanding or Beneficially Owned will
be deemed to include any Warrant Shares issuable upon exercise of the Warrants at the time of determination.

 

“Warrants” shall have the meaning assigned to it
in the preamble.

 

“Warrant Shares” shall have the meaning assigned
to it in the preamble.

 

Section 1.2.                      
General Interpretive Principles(a)               
The name assigned to this Agreement and the section captions used herein are for convenience of reference only and shall not be
construed to affect the meaning, construction or effect hereof. 

 

(b)              
Unless otherwise specified, the terms “hereof,” “herein” and similar terms refer to this Agreement as a
whole, and references herein to Articles or Sections refer to Articles or Sections of this Agreement.

 

(c)               
For purposes of this Agreement, the words, “include,” “includes” and “including,” when used
herein, shall be deemed in each case to be followed by the words “without limitation.”

 

(d)              
Any action that is required to be taken by the Non-DSM Directors or any consent that may be given by the Non-DSM Directors herein
shall require the approval or consent of a majority of the Non-DSM Directors.

 

(e)               
The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity or question of
intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties and no presumption or burden
of proof will arise favoring or disfavoring any party because of the authorship of any provision of this Agreement.

 

ARTICLE
II

GOVERNANCE

 

Section 2.1.                      
Board of Directors.

 

(a)    Board
Representation. 

 

(i)           
Following the Closing and for so long as DSM Beneficially Owns at least 4.5% of the Company’s outstanding Voting Securities,
DSM shall have the right to nominate one individual for election to the Board; provided, that such individual shall be a member of DSM Parent’s Executive Committee
(such individual, the “DSM Nominee”).

 

    	5

     

    

 

(ii)           
In the event that DSM is no longer entitled to nominate a director to the Board pursuant to Section 2.1(a)(i) above, DSM shall
promptly cause the then-serving DSM Director to immediately resign. If any such director is unwilling to resign, DSM will take
all such actions as are necessary to cause the removal of the director, including voting (or causing to be voted) all of the Voting
Securities Beneficially Owned by it in favor of such removal. 

 

(iii)           
For so long as DSM has the right to nominate a DSM Nominee for election pursuant to Section 2.1(a)(i), in connection with each
election of directors, subject to Section 2.1(a)(v), the Company shall nominate such DSM Nominee for election as a director as
part of the management slate that is included in the proxy statement of the Company relating to the election of directors. 

 

(iv)           
In the event that any DSM Director shall cease to serve as a director for any reason (other than the resignation or removal of
such director as a result of DSM not having the right to nominate a director pursuant to Section 2.1(a)(i)), subject to Section
2.1(a)(v), DSM shall have the right to designate another DSM Nominee to fill the vacancy resulting therefrom. For the avoidance
of doubt, it is understood that the failure of the stockholders of the Company to elect any DSM Nominee shall not affect the right
of DSM to designate a DSM Nominee for election pursuant to Section 2.1(a)(i) in connection with any future election of directors
of the Company. 

 

(v)           
Notwithstanding the foregoing, as a condition to any DSM Nominee’s appointment to the Board and nomination for election as
a director of the Company at the Company’s annual meetings of stockholders:

 

		(A)	DSM and such DSM Nominee must in all material respects provide to the Company (1) all information reasonably requested by the
Company that is required to be or customarily disclosed for directors, candidates for directors, and their affiliates in a proxy
statement or other filings under applicable law or regulation or stock exchange rules or listing standards, in each case, relating
to their nomination or election as a director of the Company and (2) information reasonably requested by the Company in connection
with assessing eligibility, independence and other criteria applicable to directors or satisfying compliance and legal or regulatory
obligations, in each case, relating to their nomination or election as a director of the Company, with respect to DSM Parent, its
Subsidiaries and controlled Affiliates and the applicable DSM Nominee, in each case, to the same extent as all other directors
of the Company;

 

    	6

     

    

 

		(B)	such DSM Nominee must be qualified to serve as a director of the Company under the DGCL to the same extent as all other directors
of the Company;

 

		(C)	no Disqualification Event shall be applicable to such DSM Nomine except, if applicable, for a Disqualification Event as to
which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable;

 

		(D)	such DSM Nominee shall be reasonably acceptable to the Nominating and Governance Committee of the Board; and

 

		(E)	such DSM Nominee must satisfy the requirements set forth in the Company’s Corporate Governance Guidelines, code of conduct
and securities trading policy, in each case as currently in effect with such changes thereto (or such successor policies) as are
applicable to all other directors, as are adopted in good faith by the Board, and do not by their terms adversely impact any DSM
Nominee relative to all other directors (provided that, for the avoidance of doubt, no DSM Nominee shall be required to qualify
as an independent director under applicable stock exchange rules or securities laws and regulations).

 

The Company will make all information requests pursuant to
this Section 2.1(a)(v) in good faith in a timely manner that allows DSM and the DSM Nominee a reasonable amount of time to provide
such information, and will cooperate in good faith with DSM and the DSM Nominee in connection with their efforts to provide the
requested information.

 

(vi)           
DSM hereby covenants and agrees (A) not to designate or participate in the designation of any director designee who, to DSM’s
knowledge, is a Disqualified Designee, (B) that in the event DSM becomes aware that any individual previously designated by DSM
is or has become a Disqualified Designee or that a Disqualification Event has become applicable to DSM or any of its Rule 506(d)
Related Parties, except, if applicable, for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable,
then DSM shall notify the Company promptly in writing and as promptly as practicable DSM shall take such actions as are necessary
to remove any such Disqualified Designee from the Board and designate a replacement designee who is not a Disqualified Designee,
and (C) for so long as there is a DSM Director, DSM will comply with the Company’s insider trading policy as currently in
effect with such changes thereto (or such successor policies) as are applicable to all other stockholders of the Company that have
rights to designate or nominate members of the Board.

 

(b)   Identity
of the Nominee. The initial DSM Nominee shall be Chris Goppelsroeder. The Company confirms that Mr. Goppelsroeder is reasonably
acceptable to the Nominating and Governance Committee of the Board. The Company shall cause the initial DSM Nominee to
be appointed to the Board on or prior to May 18, 2017.

 

    	7

     

    

 

 

(c)                     
D&O Indemnification. The DSM Director shall be eligible to enter into an indemnification agreement consistent with
the form generally entered into with the Company’s officers and directors. 

 

(d)                    
Committees. The DSM Director shall be entitled to serve on each standing committee of the Board other than (i) the Compensation
Committee of the Board, (ii) the Audit Committee of the Board, (iii) the Nominating and Governance Committee of the Board and (iv)
any other committee of the Board for which a DSM Director’s membership would result in a conflict of interest (including,
without limitation, any special committee formed for the purpose of evaluating any transaction between the Company and DSM Parent
and/or its Subsidiaries or controlled Affiliates). 

 

ARTICLE
III

TRANSFER RESTRICTIONS

 

Section 3.1.                      
General Transfer Restrictions. The right of DSM to Transfer any Transfer Restricted Shares
Beneficially Owned by DSM is subject to the restrictions set forth in this Article III, and no Transfer by DSM of such Transfer
Restricted Shares Beneficially Owned by DSM may be affected except in compliance with this Article III. Any attempted Transfer
in violation of this Article III shall be of no effect and null and void, regardless of whether the purported transferee has any
actual or constructive knowledge of the Transfer restrictions set forth in this Article III, and shall not be recorded on the stock
transfer books of the Company. 

 

Section 3.2.                      
Specific Transfer Restrictions. 

 

(a)    Without
the prior approval of the Non-DSM Directors, DSM shall not, and shall not permit DSM Parent or any of its other Subsidiaries or
controlled Affiliates to: 

 

(i)           
Except as permitted under Section 3.3, Transfer any Transfer Restricted Shares to any Person or Group that is or includes a Competitor;
or

 

(ii)           
Except as permitted under Section 3.3, Transfer any Transfer Restricted Shares to any Person or Group during the one-year period
immediately following the Closing. 

 

(b)   Other than with
respect to any Transfer permitted by Section 3.3, prior to any Transfer of Transfer Restricted Shares to any Person or Group, DSM
shall first provide the Company with written notice of its intent to Transfer any Transfer Restricted Shares not later than thirty
(30) days prior to the consummation of such proposed Transfer. Thereafter, DSM agrees to negotiate in good faith with the Company
with respect to the purchase by the Company or any other third parties introduced to DSM by the Company of such Transfer Restricted
Shares subject to such proposed Transfer.

 

    	8

     

    

 

(c)    DSM acknowledges
that the Restricted Shares have not been registered under the Securities Act and may not be Transferred except pursuant to an effective
registration statement under the Securities Act or pursuant to an exemption from registration under the Securities Act. DSM covenants
that the Restricted Shares will only be disposed of pursuant to an effective registration statement under, and in compliance with
the requirements of, the Securities Act or pursuant to an available exemption from the registration requirements of the Securities
Act, and in compliance with any applicable state and foreign securities laws. In connection with any Transfer of Restricted Shares
other than pursuant to an effective registration statement or to the Company, or pursuant to Rule 144, the Company may require
DSM to provide to the Company an opinion of counsel selected by the DSM and reasonably acceptable to the Company, the form and
substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such Transfer does not require registration
under the Securities Act. Notwithstanding the foregoing, the Company hereby consents to and agrees to register on the books of
the Company and with its transfer agent, without any legal opinion, except to the extent that the transfer agent requests such
legal opinion, any Transfer of Restricted Shares by DSM to DSM Parent or another Subsidiary or controlled Affiliate of DSM Parent,
provided that the Transfer is effected in accordance with Section 3.3. 

 

(d)   DSM agrees to
the imprinting, so long as is required by this Section 3.2, of the following legend on any certificate evidencing any of
the Restricted Shares: 

 

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE
HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED
INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

Certificates evidencing the Restricted Shares shall not be required to
contain such legend or any other legend (i) following any sale of such Restricted Shares pursuant to an effective
registration statement (including the Registration Statement) covering the resale of the Restricted Shares,
(ii) following any sale of such Restricted Shares pursuant to Rule 144 if the holder provides the Company with a
legal opinion reasonably acceptance to the Company to the effect that the Restricted Shares were sold under Rule 144 or
(iii) if the holder provides the Company with a legal opinion reasonably acceptable to the Company to the effect
that the legend is not required under applicable requirements of the Securities Act. Notwithstanding anything to the contrary
in this Agreement or the Securities Purchase Agreement, in the event of any conflict or inconsistency between any provision
of Section 3.2(d), Section 3.2(d) or Article V of this Agreement, on the one hand, and any provision of the Securities
Purchase Agreement, on the other hand, whichever provision is more favorable to DSM under the circumstances (as determined by
DSM in its sole discretion) will control as between the Company and DSM.

 

    	9

     

    

 

Section 3.3.                      
Permitted Transfers.

 

(a)    DSM may
Transfer any or all of the Transfer Restricted Shares held by it (i) to DSM Parent or any of its other Subsidiaries or controlled
Affiliates, provided that, at or prior to the Transfer, such transferee shall have agreed with the Company in writing to
be bound by all of the terms and condition of this Agreement applicable to DSM, or (ii) in connection with a Change of Control
Transaction or Fundamental Transaction (as such term is defined in the Company’s Certificate of Designation of Preferences,
Rights and Limitations of Series B 17.38% Convertible Preferred Stock), at the consummation of (and pursuant to the terms of) such
transaction.

 

(b)   Notwithstanding
anything herein to the contrary, no change in control or ownership of any shares in the capital stock of DSM Parent shall constitute
a Transfer for purposes of this Agreement. 

 

ARTICLE
IV 

 

SHARE
OWNERSHIP

 

Section 4.1.                      
Standstill. 

 

(a)    Except
as provided in Section 4.1(b), from the Closing until three months after no DSM Nominee serves on the Board (the “Standstill
Period”), DSM shall not, nor shall it permit DSM Parent or any of its other Subsidiaries or controlled Affiliates to,
directly or indirectly, without the prior consent of the Company (acting through a resolution of the Company’s Non-DSM Directors):

 

(i)           
acquire or agree to acquire, whether by purchase, tender or exchange offer, by forming, joining or otherwise participating in
a partnership, syndicate or other Group, through the use of a derivative instrument or voting agreement, or otherwise, (A) Beneficial
Ownership of additional Voting Securities or Convertible Securities after the Closing that would result in DSM Parent (together
with its Subsidiaries or controlled Affiliates and any parties acting as members of a Group with DSM), having Beneficial Ownership
of more than 33.0% in the aggregate of the shares of Voting Securities outstanding at such time (assuming (1) the exercise of
all of then-outstanding Warrants for the maximum number of shares of Common Stock issuable thereunder, regardless of whether
such Warrants are then exercisable, (2) the conversion of the Shares for the maximum number of shares of Common Stock issuable
thereunder, regardless of whether such Shares are then convertible, and (3) the exercise or conversion, as applicable, of any
Tranche II Securities for the maximum number of shares of Common Stock issuable thereunder, regardless of whether such Tranche
II Securities are then exercisable or convertible, as the case may be, which number of shares shall be included in the numerator
and denominator for purposes of determining the percentage of Voting Securities Beneficially Owned by DSM Parent (together with
its Subsidiaries and controlled Affiliates and any parties acting as members of a Group with DSM) for purposes of this clause
(A)), except pursuant to Section 4.2 or Section 6.4 of this Agreement, pursuant to the exercise of the Warrants or any warrants
that constitute Tranche II Securities, pursuant to the Securities Purchase Agreement or pursuant to the Company’s Certificate
of Designation of Preferences, Rights and Limitations of Series B 17.38% Convertible Preferred Stock, or (B) any direct or indirect
ownership interest in any indebtedness or debt securities of the Company or any of its Subsidiaries, except pursuant to Section
4.2 of this Agreement;

 

    	10

     

    

 

(ii)           
(A) make, or in any way participate, directly or indirectly, in any “solicitation” of “proxies” (as such
terms are used in the rules of the SEC) to vote Voting Securities, (B) seek to advise or knowingly influence any Person with respect
to the voting of any Voting Securities or (C) deposit any Voting Securities in any voting trust or subject any Voting Securities
to any arrangement or agreement with respect to the voting of any Voting Securities, except for this Agreement;

 

(iii)           
make any public announcement of a proposal or offer (with or without conditions) with respect to any extraordinary transaction
involving DSM Parent or its Subsidiaries or controlled Affiliates and the Company including, without limitation, any tender offer,
merger, consolidation or business combination; 

 

(iv)           
effect or seek to effect any recapitalization, reclassification, liquidation or dissolution of the Company;

 

(v)           
publicly disclose any intention, plan or arrangement by DSM regarding the possibility of any of the events described in clauses
(i) through (iv) above; 

 

(vi)           
knowingly take any action that would require either the Company or DSM under applicable law or the rules of the principal exchange
on which the Company’s Common Stock is then listed or traded to make a public announcement regarding the possibility of any
of the events described in clauses (i) through (iv) above; or

 

(vii)           
enter into any discussions, negotiations, agreements or understandings with any other third Person (excluding DSM’s advisors)
with respect to any of the foregoing.

 

(b)   Notwithstanding
the foregoing, the restrictions contained in Section 4.1(a) shall not (1) apply with respect to the designation of the DSM Nominees
in accordance with this Agreement, (2) prevent a DSM Director from taking any action in his or her capacity as a director of the
Company, (3) prohibit DSM Parent or any of its Subsidiaries or controlled Affiliates from voting its Voting Securities in its discretion,
(4) apply to the acquisition of securities in or control of another Person (including by way of merger or consolidation) or (5)
apply to any acquisitions or investments by any bona fide employee benefit plan of DSM Parent or its Subsidiaries or controlled
Affiliates. In addition, the restrictions contained in Section 4.1(a) shall not prevent a private communication to the Board to
the extent that such private communication would not reasonably be expected to require a public disclosure prior to any public
announcement by the Company that it (or its Board) has approved or entered into an agreement with respect to a Change of Control
Transaction or Fundamental Transaction.

 

    	11

     

    

 

Section 4.2.                      
Preemptive Rights. 

 

(a)    Other
than as set forth in Section 4.2(d) and (e), if the Company or any Subsidiary of the Company at any time shall propose to issue
any Voting Securities or Convertible Securities or any other equity or equity-linked securities (including, for the avoidance of
doubt, convertible debt) following the Closing in a capital raising transaction for cash (other than pursuant to the Securities
Purchase Agreement) (a “Post-Closing Issuance”), DSM shall have the right to purchase for cash directly from
the Company or such Subsidiary up to its Ownership Percentage of such Participation Shares at the same purchase price as the price
for the Participation Shares to be issued. 

 

(b)   With respect
to any Post-Closing Issuance, the Company, on behalf of itself or its applicable Subsidiary, will notify DSM in writing (the “Notice”)
stating (i) its bona fide intention to offer such Participation Securities, (ii) the number of such Participation Securities to
be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Participation Securities. 

 

(c)    Within
thirty (30) business days after giving of the Notice, DSM may elect to purchase or obtain, at the price and on the terms specified
in the Notice, up to its Ownership Percentage of such Participation Shares. DSM shall be entitled to allocate, as among DSM Parent
and its Subsidiaries and controlled Affiliates (who agree or have agreed in writing to be bound by the terms of this Agreement),
the number of Participation Shares entitled to be purchased by DSM Parent and its Subsidiaries and controlled Affiliates (collectively)
pursuant to this Section 4.2. In the event that DSM elects to exercise its purchase rights pursuant to this Section 4.2, DSM shall
provide to the Company written notice of such election (the “Election Notice”) to purchase up to its Ownership
Percentage of the Participation Shares hereunder, which notice shall (i) certify the Ownership Amount as of the date of the Election
Notice, (ii) specify the number of Participation Shares to be purchased by DSM Parent and its Subsidiaries and controlled Affiliates
(not to exceed DSM’s Ownership Percentage of the Participation Shares, the “Specified Number”), and (iii)
the allocation of such Participation Shares among DSM Parent and its Subsidiaries and controlled Affiliates. DSM shall, or shall
cause DSM Parent and its other Subsidiaries and controlled Affiliates (as applicable) to, purchase, and the Company shall, or shall cause its applicable Subsidiary
to, issue and sell to DSM Parent and its Subsidiaries and controlled Affiliates (as applicable), the Specified Number of the Participation
Shares concurrently with the related Post-Closing Issuance by the Company or its applicable Subsidiary.

 

    	12

     

    

 

(d)   In the event
that the Post-Closing Issuance which gave rise to the exercise by DSM of its purchase rights pursuant to this Section 4.2 shall
be terminated or abandoned by the Company without the issuance of any securities, then the purchase rights of DSM pursuant to this
Section 4.2 shall also terminate as to such proposed Post-Closing Issuance (but not any subsequent or future issuance), and any
funds in respect thereof paid to the Company by DSM shall be refunded in full.

 

(e)    Notwithstanding
the foregoing, the provisions of this Section 4.2 shall not apply to, and DSM shall not have any purchase rights with respect to,
any of the following types of Post-Closing Issuances by the Company or any of its Subsidiaries:

 

(i)           
any Post-Closing Issuance of Voting Securities or Convertible Securities to officers, employees, directors or consultants of the
Company in connection with such Person’s employment or consulting arrangements with the Company or the service of such person
as a director;

 

(ii)           
any Post-Closing Issuance of Voting Securities or Convertible Securities (i) in any business combination or acquisition transaction
involving the Company or any of its Subsidiaries or (ii) in connection with the incurrence of indebtedness by the Company or any
of its Subsidiaries (provided that such indebtedness does not constitute a Convertible Security);

 

(iii)           
any Post-Closing Issuance of Voting Securities or Convertible Securities in connection with any stock split, stock dividend or
recapitalization approved by the Board (so long as all holders of the same class or series of Voting Securities is treated equally
with all other holders of such class or series of Voting Securities); or

 

(iv)           
any Post-Closing Issuance of Voting Securities pursuant to a public offering registered under the Securities Act; or

 

(v)           
any Post-Closing Issuance of Voting Securities or Convertible Securities to any Person (or any Affiliate of a Person), which is
an operating company or an owner of an asset in a business synergistic with the Company’s business as determined in good
faith by the Board, to induce such Person to enter into any joint venture or other strategic or commercial relationship with the
Company or any of its Subsidiaries that provides to the Company additional benefits in addition to the investment of funds, as
determined in good faith by the Non-DSM Directors, but shall not include a transaction in which the Company or any of its Subsidiaries
is issuing securities primarily for the purpose of raising capital or to a Person whose primary business is investing in securities
of other Persons.

 

    	13

     

    

 

(f)    The Company
may, during the seventy-five (75) day period following the expiration of the period provided in Section 4.2(c) hereof, offer the
remaining unsubscribed portion of such Participation Securities to any Person or Persons at a price not less than, and upon terms
no more favorable to the offeree than, those specified in the Notice. If the Company does not consummate the sale of such Participation
Securities, or enter into a definitive agreement for the sale of such Participation Securities, within such period, or if the Company
enters into such a definitive agreement and such agreement is not consummated within seventy-five (75) days of the execution
thereof, the purchase right pursuant to this Section 4.2 shall be deemed to be revived and no such Participation Securities shall
be offered unless first reoffered to DSM in accordance herewith.

 

ARTICLE
V

REGISTRATION RIGHTS

 

The Company hereby grants to each of the Holders (as defined below)
the registration rights set forth in this Article V, with respect to the Registrable Securities (as defined below) owned by such
Holders.

 

Section 5.1.                      
Certain Definitions. As used in this Article V:

 

(a)    “Effective
Date” means the date that the Initial Registration Statement has been declared effective by the SEC.

 

(b)   “Effectiveness
Deadline” means the date which is 225 days after the Closing.

 

(c)    “Filing
Deadline” means the date which is 180 days after the Closing.

 

(d)   “Holder”
(collectively, “Holders”) means (i) DSM and (ii) any subsidiary or controlled Affiliate of DSM Parent that
DSM designates in writing as a Holder, in each case to the extent holding Registrable Securities, securities exercisable or convertible
into Registrable Securities or securities exercisable for securities convertible into Registrable Securities.

 

(e)    “Prospectus”
means the prospectus included in any Registration Statement, all amendments and supplements to such prospectus, including post-effective
amendments, and all other material incorporated by reference in such prospectus.

 

(f)    “register”,
“registered” and “registration” refer to a registration effected by filing with the SEC a
Registration Statement in compliance with the Securities Act, and the declaration or ordering by the SEC of the effectiveness of
such Registration Statement.

 

(g)  
“Registrable Securities” means (i) Underlying Shares held by, or issuable to, Holders and (ii) any
shares of Voting Securities issued as (or issuable upon) a stock split, stock dividend or other distribution with respect to,
or in exchange or in replacement of, such Registrable Securities set forth in clause (i), in each case, until the earliest
to occur of (A) the date on which a Registration Statement covering such securities has been declared effective by the SEC
and such security has been disposed of pursuant to such effective Registration Statement, (B) the date on which such security
is sold pursuant to Rule 144, (C) the date on which such security ceases to be outstanding, (D) the date on which the Holder
thereof, together with its Affiliates, is able to dispose of all of its Registrable Securities in any 90 day period pursuant
to Rule 144 (or any similar or analogous rule promulgated under the Securities Act) or (E) five (5) years from the date
hereof.

 

    	14

     

    

 

(h)   “Registration
Statement” means a registration statement or registration statements of the Company filed under the Securities Act covering
the Registrable Securities.

 

(i)    
“Required Registration Amount” means the lesser of (i) 100% of the sum of the maximum number of Underlying
Shares issued and issuable as of the Trading Day immediately preceding the applicable date of determination or (ii) such other
amount as may be required by the staff of the SEC pursuant to Rule 415 with any cutback applied pro rata to all Holders. 

 

(j)                      
“Underlying Shares” means the shares of Common Stock issuable upon conversion of the Shares, the Warrant Shares
and any shares of Common Stock issuable upon conversion or exercise, as applicable, of the Tranche II Securities. 

 

Section 5.2.                      
Registration

 

(a)    (i)Initial
Mandatory Registration. The Company shall use reasonable efforts to prepare, and, as soon as practicable, but in no event later
than the Filing Deadline, file with the SEC a Registration Statement on Form S-3 covering the resale of all of the Registrable
Securities (the “Initial Registration Statement”). The Initial Registration Statement prepared pursuant hereto
shall register for resale at least the number of shares of Common Stock equal to the Initial Required Registration Amount determined
as of the date the Initial Registration Statement is initially filed with the SEC. The Company shall use its reasonable best efforts
to have the Initial Registration Statement declared effective by the SEC as soon as practicable, but in no event later than the
Initial Effectiveness Deadline. The Company shall use its reasonable efforts to file with the SEC in accordance with Rule 424 under
the Securities Act the final prospectus to be used in connection with sales pursuant to such Initial Registration Statement by
9:30 am on the Business Day following the Effective Date, but in any case no later than the deadline required by Rule 424.

 

(ii)           
Additional Registrations. Notwithstanding anything herein to the contrary, to the extent the staff of the SEC does not
permit all of the Registrable Securities to be registered on the Initial Registration Statement, the Company shall file additional
Registration Statements successively trying to register on each such Registration Statement the maximum number of remaining Registrable
Securities until all of the Registrable Securities have been registered for resale. Each such additional Registration Statement
prepared pursuant hereto shall register for resale at least that number of shares of Common Stock equal to the Additional
Registrable Securities determined as of the date such Additional Registration Statement is initially filed with the SEC. The Company
shall use its reasonable efforts to have each such additional Registration Statement declared effective by the SEC as soon as
practicable. The Company shall file with the SEC in accordance with Rule 424 under the Securities Act the final prospectus to
be used in connection with sales pursuant to such additional Registration Statement by 9:30 am on the Business Day following the
effective date of such Registration Statement, but in any case no later than the deadline required by Rule 424.

 

    	15

     

    

 

(iii)           
Underwritten Registrations. With respect to any of the registrations contemplated by this Section 5.2(a), DSM may request
that up to three such registrations provide for an underwritten offering of the Registrable Securities. In connection with any
such underwritten offering, the right of any Holder to registration pursuant to this Section 5.2(a)(iv) shall be conditioned upon
such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting
to the extent provided herein in subject to the limitations expressed in this Section 5.2. All Holders proposing to distribute
their Registrable Securities through such underwriting shall, together with any other parties distributing their securities through
such underwriting, enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting by the Company. Notwithstanding any other provision of this Section 5.2, if the underwriter determines that marketing
factors require a limitation of the number of shares to be underwritten, the underwriter may limit the number of Registrable Securities
to be included in the registration and underwriting.

 

(iv)           
Subject to the provisions of this Section 5.2 and further subject to the availability of a Registration Statement on Form S-3 (or
any successor form thereto) to the Company pursuant to the Securities Act and the rules and interpretations of the SEC, the Company
will use its reasonable efforts to keep the Initial Registration Statement (or any replacement Registration Statement) continuously
effective until the earlier of: (A) the date on which all Registrable Securities covered by the Registration Statement have been
sold thereunder in accordance with the plan and method of distribution disclosed in the prospectus included in the Registration
Statement and (B) there otherwise cease to be any Registrable Securities.

 

(v)           
Allocation of Registrable Securities. The initial number of Registrable Securities included in any Registration Statement
and any increase or decrease in the number of Registrable Securities included therein shall be allocated pro rata among the Holders
based on the number of Registrable Securities held by each Holder at the time the Registration Statement covering such initial
number of Registrable Securities or increase or decrease thereof is declared effective by the SEC. In the event that a Holder
sells or otherwise transfers any of such Holder’s Registrable Securities, each transferee that becomes a Holder shall be
allocated a pro rata portion of the then remaining number of Registrable Securities included in such Registration Statement for
such transferor. Any shares of Common Stock included in a Registration Statement and which remain allocated to any Person which
ceases to hold any Registrable Securities covered by such Registration Statement shall be allocated to the remaining Holders,
pro rata based on the number of Registrable Securities then held by such Holders which are covered by such Registration Statement.

 

    	16

     

    

 

(b)   Suspension
of Filing or Registration. If the Company shall furnish to the Holders a certificate signed by the Chief Executive Officer
or Chief Financial Officer of the Company, stating that the filing, effectiveness or continued use of a Registration Statement
would require the Company to make an Adverse Disclosure, then the Company shall have a period of not more than 75 days (or such
longer period as DSM shall consent to in writing) within which to delay the filing or effectiveness of such Registration Statement
or, in the case of a Registration Statement that has been declared effective, to suspend the use by Holders of such Registration
Statement (in each case, a “Shelf Suspension”); provided, however, that, unless consented to in
writing by the DSM, the Company shall not be permitted to exercise a Suspension more than twice during any 12-month period for
each Shelf Registration Statement. In the case of a Shelf Suspension that occurs after the effectiveness of a Registration Statement,
the Holders agree to suspend use of the applicable Prospectus in connection with any sale or purchase of, or offer to sell or purchase,
Registrable Securities, upon receipt of the notice referred to above. The Company shall immediately notify the Holders upon the
termination of any Shelf Suspension, and (i) in the case of a Registration Statement that has not been declared effective, shall
promptly thereafter file a Registration Statement and use its reasonable best efforts to have such Registration Statement declared
effective under the Securities Act and (ii) in the case of an effective Registration Statement, shall amend or supplement the Prospectus,
if necessary, so it does not contain any untrue statement or omission and furnish to the Holders such numbers of copies of the
Prospectus as so amended or supplemented as the Holders may reasonably request. The Company agrees, if necessary, to supplement
or make amendments to the applicable Registration Statement, if required by the registration form used by the Company for the shelf
registration or by the instructions applicable to such registration form or by the Securities Act or the rules or regulations promulgated
thereunder.

 

(c)    The
Company shall use its commercially reasonable efforts to take all actions reasonably necessary to ensure that the transactions
contemplated herein are effected as so contemplated in Section 5.2(a) hereof, and to submit to the SEC, within five Business
Days after the Company learns that no review of a Registration Statement will be made by the staff of the SEC or that the staff
has no further comments on a Shelf Registration Statement, as the case may be, a request for acceleration of effectiveness (or
post effective amendment, if applicable) of such Registration Statement to a time and date not later than 48 hours after the submission
of such request. 

 

(d)   Any reference
herein to a registration statement or prospectus as of any time shall be deemed to include any document incorporated, or deemed
to be incorporated, therein by reference as of such time and any reference herein to any post-effective amendment to a registration
statement as of any time shall be deemed to include any document incorporated, or deemed to be incorporated, therein by reference
as of such time. Any reference to a prospectus as of any time shall include any supplement thereto, preliminary prospectus, or
any free writing prospectus in respect thereof. 

 

    	17

     

    

 

(e)    In
connection with the filing of a Registration Statement, the Company shall: 

 

(i)           
prepare and file with the SEC within the time periods specified in Section 5.2(a), a Registration Statement on any form which
may be utilized by the Company and which shall register all of the Registrable Securities for resale by the holders thereof in
accordance with such method or methods of disposition (but which shall not include an underwritten offering as to which the Company
needs to assist) as may be specified by DSM and use reasonable best efforts to cause such Registration Statement to become effective
as soon as reasonably practicable but in any case within the time periods specified in Section 5.2(a); 

 

(ii)           
as soon as reasonably practicable prepare and file with the SEC such amendments and supplements to such Registration Statement
(including without limitation, any required post effective amendments) and the prospectus included therein as may be necessary
to effect and maintain the effectiveness of such Registration Statement for the period specified in Section 5.2(a) hereof
and as may be required by the applicable rules and regulations of the SEC and the instructions applicable to the form of such Registration
Statement; 

 

(iii)           
comply with the provisions of the Securities Act with respect to the disposition of all of the Registrable Securities covered by
such Registration Statement in accordance with the intended methods of disposition by DSM provided for in such Registration Statement;

 

(iv)           
provide DSM and its legal counsel (“Legal Counsel”) a reasonable opportunity to participate in the preparation
of such Registration Statement, each prospectus included therein or filed with the SEC and each amendment or supplement thereto
(but not including any documents incorporated by reference), in each case subject to customary confidentiality restrictions, and give
reasonable consideration to any comments Legal Counsel provides with respect to any Shelf Registration Statement or amendment or
supplement thereto. The Company shall furnish to Legal Counsel copies of any correspondence from the SEC or the staff of the SEC
to the Company or its representatives relating to any Registration Statement; 

 

(v)           
promptly notify DSM (A) when such Registration Statement or the Prospectus included therein or any prospectus amendment or
supplement or post-effective amendment has been filed, and, with respect to such Registration Statement or any post-effective
amendment, when the same has become effective, (B) of any comments by the SEC with respect thereto or any request by the
SEC for amendments or supplements to such Registration Statement or prospectus or for additional information, (C) of the
issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement or the initiation or threatening
of any proceedings for that purpose, (D) of the receipt by the Company of any notification with respect to the suspension
of the qualification of the Registrable Securities for sale in any jurisdiction or the initiation or threatening of any proceeding
for such purpose, or (E) if at any time when a prospectus is required to be delivered under the Securities Act, that such
Registration Statement, prospectus, prospectus amendment or supplement or post-effective amendment does not conform in
all material respects to the applicable requirements of the Securities Act and the rules and regulations of the SEC thereunder
or contains an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary
to make the statements therein not misleading in light of the circumstances then existing; and

 

    	18

     

    

 

(vi)           
in the event that Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company
shall (i) register the resale of the Registrable Securities on another appropriate form reasonably acceptable to DSM and (ii) undertake
to register the Registrable Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain
the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering
the Registrable Securities has been declared effective by the SEC. 

 

(f)    In
connection with a shelf registration, the Company may require each Holder whose Registrable Securities are covered by the shelf
registration, to furnish to the Company such information regarding the Holder, including, without limitation, its intended method
of distribution of Registrable Securities as may be required in order to comply with the Securities Act. The Holder agrees to notify
the Company as promptly as practicable of any inaccuracy or change in information previously furnished by the Holder to the Company
or of the occurrence of any event in either case that could cause the prospectus to contain an untrue statement of a material fact
regarding the Holder or its intended method of disposition of such Registrable Securities or omits to state any material fact regarding
the Holder or its intended method of disposition of such Registrable Securities required to be stated therein or necessary to make
the statements therein not misleading in light of the circumstances then existing, and promptly to furnish to the Company any additional
information required to correct and update any previously furnished information or required so that such prospectus shall not contain,
with respect to the Holder or the disposition of such Registrable Securities, an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances then existing. If the Holder fails to provide to the Company any information required to be provided pursuant to
this Section 5.2 after the Holder became aware of the inaccuracy, omission or required change, the Company may suspend the
use of the Registration Statement and the prospectus contained therein until such time as the Holder provides the required information
to the Company.

 

Section 5.3.                      
Piggyback Registration.

 

(a)   
Company Registration. If at any time or from time to time the Company shall determine to register any of its
equity securities, either for its own account or for the account of security holders (other than (1) in a registration
relating solely to employee benefit plans, (2) a registration on Form S-4 or S-8 (or such other similar successor forms then
in effect under the Securities Act), (3) a primary registration of securities under Rule 415 of the Securities Act,
(4) a registration pursuant to which the Company is offering to exchange its own securities, (5) a registration
statement relating solely to dividend reinvestment or similar plans, (6) a resale shelf registration statement relating
solely to debt securities of the Company that are convertible into Common Stock and the underlying shares of Common Stock or
(7) a registration pursuant to Section 5.2), the Company will:

 

    	19

     

    

 

(i)           
promptly (but in no event less than 10 days before the effective date of the relevant Registration Statement) give to each Holder
written notice thereof; and

 

(ii)           
include in such registration (and any related qualification under state securities laws or other compliance), and in any underwriting
involved therein, all the Registrable Securities specified in a written request or requests, made within 5 days after receipt of
such written notice from the Company, by any Holder or Holders, subject, in each case, to the limitations expressed in Section 5.2
and except as set forth in Section 5.3(b) below.

 

(b)   Underwriting.
If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company
shall so advise the Holders as a part of the written notice given pursuant to Section 5.3(a)(i). In such event the right of any
Holder to registration pursuant to this Section 5.3 shall be conditioned upon such Holder’s participation in such underwriting
and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein in subject to
the limitations expressed in Section 5.2. All Holders proposing to distribute their Registrable Securities through such underwriting
shall, together with the Company and the other parties distributing their securities through such underwriting, enter into an underwriting
agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding
any other provision of this Section 5.3, if the underwriter determines that marketing factors require a limitation of the number
of shares to be underwritten, the underwriter may limit the number of Registrable Securities to be included in the registration
and underwriting, subject to the terms of this Section 5.3. The Company shall so advise all holders of the Company’s securities
that would otherwise be registered and underwritten pursuant hereto, and the number of shares of such securities, including Registrable
Securities, that may be included in the registration and underwriting shall be allocated first to the Company and second
to the Holders and any other holders with registration rights on a pro rata basis based on the total number of Registrable Securities
held by the Holders and such other holders. No such reduction shall (i) reduce the securities being offered by the Company for
its own account to be included in the registration and underwriting, or (ii) subject to the limitations expressed in Section 5.2,
reduce the amount of securities of the selling Holders included in the registration below twenty-five percent (25%) of the total
amount of securities included in such registration by all selling stockholders. No securities excluded from the underwriting by
reason of the underwriter’s marketing limitation shall be included in such registration. For the avoidance of doubt, nothing
in this Section 5.3(b) is intended to diminish the number of securities to be included by the Company in the underwriting.

 

 

    	20

     

    

 

(c)    Right
to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this Section 5.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in
such registration.

 

Section 5.4.                      
Expenses of Registration. All expenses incurred in connection with all registrations effected
pursuant to Sections 5.2 and 5.3, including all registration, filing and qualification fees (including state securities law fees
and expenses), printing expenses, escrow fees, fees and disbursements of counsel for the Company; provided, however,
that the Company shall not be required to pay the fees of Legal Counsel, stock transfer taxes or underwriters’ discounts
or selling commissions relating to Registrable Securities. 

 

Section 5.5.                      
Obligations of the Company. Whenever required under this Article V to effect the registration
of any Registrable Securities, the Company shall (in addition to the requirements set forth in Section 5.2(e) with respect to a
Registration Statement), as expeditiously as reasonably possible:

 

(a)    prepare
and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in connection with
such Registration Statement as may be necessary to keep such Registration Statement effective and to comply with the provisions
of the Securities Act with respect to the disposition of all securities covered by such registration statement in accordance with
the intended methods of disposition by sellers thereof set forth in such registration statement;

 

(b)   permit any
Holder which Holder, in the reasonable judgment of the Company, if deemed to be a controlling person of the Company, to participate
in good faith in the preparation of such Registration Statement and to cooperate in good faith to include therein material, furnished
to the Company in writing, that in the reasonable judgment of the Company should be included;

 

(c)    furnish
to the Holders such numbers of copies of a prospectus, including all exhibits thereto and documents incorporated by reference therein
and a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably
request in order to facilitate the disposition of Registrable Securities owned by them;

 

(d)   in the event
of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and
perform its obligations under such an agreement;

 

(e)    notify
each Holder of Registrable Securities covered by such Registration Statement as soon as reasonably practicable after notice thereof
is received by the Company of any written comments by the SEC or any request by the SEC or any other federal or state governmental
authority for amendments or supplements to such Registration Statement or such prospectus or for additional information;

 

    	21

     

    

 

(f)    notify
each Holder of Registrable Securities covered by such Registration Statement, at any time when a prospectus relating thereto is
required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in
such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then
existing;

 

(g)   notify each
Holder of Registrable Securities covered by such Registration Statement as soon as reasonably practicable after notice thereof
is received by the Company of the issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement
or any order by the SEC or any other regulatory authority preventing or suspending the use of any preliminary or final prospectus
or the initiation or threatening of any proceedings for such purposes, or any notification with respect to the suspension of the
qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or threatening of any proceeding
for such purpose;

 

(h)   use its
reasonable efforts to prevent the issuance of any stop order suspending the effectiveness of any Registration Statement or of any
order preventing or suspending the use of any preliminary or final prospectus and, if any such order is issued, to obtain the withdrawal
of any such order as soon as practicable;

 

(i)    
in the case of an underwritten offering, make available for inspection, at the Company's headquarters during normal business
hours, by each Holder including Registrable Securities in such registration, any underwriter participating in any distribution
pursuant to such registration, and any attorney, accountant or other agent retained by such Holder or underwriter, all financial
and other records, pertinent corporate documents and properties of the Company, as such parties may reasonably request, and cause
the Company’s officers, directors and employees to supply all information reasonably requested by any such Holder, underwriter,
attorney, accountant or agent in connection with such Registration Statement;

 

(j)    
use its reasonable efforts to register or qualify, and cooperate with the Holders of Registrable Securities covered by such
Registration Statement, the underwriters, if any, and their respective counsel, in connection with the registration or qualification
of such Registrable Securities for offer and sale under the securities or “blue sky” laws of each state and other jurisdiction
of the United States as any such Holder or underwriters, if any, or their respective counsel reasonably request in writing, and
do any and all other things reasonably necessary or advisable to keep such registration or qualification in effect for such period
as required by Section 5.2(a), as applicable; provided that the Company shall not be required to qualify generally to do
business in any jurisdiction where it is not then so qualified or take any action which would subject it to taxation or general
service of process in any such jurisdiction where it is not then so subject;

 

(k)   in
the case of an underwritten offering, obtain for delivery to the underwriters, if any, an opinion or opinions from counsel
for the Company, dated the effective date of the Registration Statement or, in the event of an underwritten offering,
the date of the closing under the underwriting agreement, in customary form, scope and substance, which opinions shall be
reasonably satisfactory to such underwriters and their respective counsel;

 

    	22

     

    

 

(l)    
in the case of an underwritten offering, obtain for delivery to the Company and the underwriters, a cold comfort letter from
the Company’s independent certified public accountants in customary form and covering such matters of the type customarily
covered by cold comfort letters as managing underwriter or underwriters reasonably request, dated the date of execution of the
underwriting agreement and brought down to the closing under the underwriting agreement;

 

(m)        use
its reasonable efforts to list the Registrable Securities covered by such Registration Statement with any securities exchange on
which the Common Stock is then listed;

 

(n)   provide
and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by the applicable Registration
Statement from and after a date not later than the effective date of such Registration Statement;

 

(o)   cooperate
with Holders including Registrable Securities in such registration and the underwriters, if any, to facilitate the timely preparation
and delivery of certificates representing Registrable Securities to be sold, such certificates to be in such denominations and
registered in such names as such Holders or the managing underwriters may request at least two Business Days prior to any sale
of Registrable Securities; and

 

(p)   use its
reasonable efforts to comply with all applicable securities laws and make available to its Holders, as soon as reasonably practicable,
an earnings statement satisfying the provisions of Section 11(a) of the Securities Act and the rules and regulations promulgated
thereunder.

 

Section 5.6.                      
Indemnification.

 

(a)    The
Company will, and does hereby undertake to, indemnify and hold harmless each Holder of Registrable Securities, each of such Holder’s
officers, directors, employees, partners and agents, and each Person controlling such Holder, with respect to any registration,
qualification or compliance effected pursuant to this Article V, and each underwriter, if any, and each Person who controls any
underwriter, of the Registrable Securities held by or issuable to such Holder, against all claims, losses, damages and liabilities
(or actions in respect thereto) to which they may become subject under the Securities Act, the Exchange Act, or other federal
or state law arising out of or based on (A) any untrue statement (or alleged untrue statement) of a material fact contained in
any prospectus, offering circular or other similar document (including any related Registration Statement, notification, or the
like) incident to any such registration, qualification or compliance, or based on any omission (or alleged omission) to state
therein a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances in which they were made, (B) any violation or alleged violation by the Company of any federal, state or common
law rule or regulation applicable to the Company in connection with any such registration, qualification or compliance, or (C)
any failure to register or qualify Registrable Securities in any state where the Company or its agents have affirmatively undertaken
or agreed in writing that the Company (the undertaking of any underwriter chosen by the Company being attributed to the Company)
will undertake such registration or qualification on behalf of the Holders of such Registrable Securities (provided that
in such instance the Company shall not be so liable if it has undertaken its reasonable efforts to so register or qualify such
Registrable Securities) and will reimburse, as incurred, each such Holder, each such underwriter and each such director, officer,
partner, agent and controlling person, for any legal and any other expenses reasonably incurred in connection with investigating
or defending any such claim, loss, damage, liability or action; provided that the Company will not be liable in any such
case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or
omission made in reliance and in conformity with written information furnished to the Company by such Holder or underwriter expressly
for use therein.

 

    	23

     

    

 

(b)   Each Holder
will, and if Registrable Securities held by or issuable to such Holder are included in such registration, qualification or compliance
pursuant to this Article V, does hereby undertake to indemnify and hold harmless the Company, each of its directors, employees,
agents and officers, and each Person controlling the Company, each underwriter, if any, and each Person who controls any underwriter,
of the Company’s securities covered by such a Registration Statement, and each other Holder, each of such other Holder’s
officers, partners, directors and agents and each Person controlling such other Holder, against all claims, losses, damages and
liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a
material fact contained in any such Registration Statement, prospectus, offering circular or other document, or any omission (or
alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not
misleading in light of the circumstances in which they were made, and will reimburse, as incurred, the Company, each such underwriter,
each such other Holder, and each such director, officer, employee, agent, partner and controlling Person of the foregoing, for
any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage,
liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement)
or omission (or alleged omission) was made in such Registration Statement, prospectus, offering circular or other document, in
reliance upon and in conformity with written information furnished to the Company by such Holder expressly for use therein; provided,
however, that the liability of each Holder hereunder shall be limited to the net proceeds received by such Holder from the
sale of securities under such Registration Statement. It is understood and agreed that the indemnification obligations of each
Holder pursuant to any underwriting agreement entered into in connection with any Registration Statement shall be limited to the
obligations contained in this subsection 5.6(b).

 

(c)    Each
party entitled to indemnification under this Section 5.6 (the “Indemnified Party”) shall give notice to the
party required to provide such indemnification (the “Indemnifying Party”) of any claim as to which indemnification
may be sought promptly after such Indemnified Party has actual knowledge thereof, and shall permit the Indemnifying Party to assume
the defense of any such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party,
who shall conduct the defense of such claim or litigation, shall be subject to approval by the Indemnified Party (whose approval
shall not be unreasonably withheld) and the Indemnified Party may participate in such defense at the Indemnifying Party’s
expense if representation of such Indemnified Party would be inappropriate due to actual or potential differing interests between
such indemnified party and any other party represented by such counsel in such proceeding; and provided further that the
failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations
under this Article V, except to the extent that such failure to give notice shall materially adversely affect the Indemnifying
Party in the defense of any such claim or any such litigation. An Indemnifying Party, in the defense of any such claim or litigation,
may, without the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that includes
as an unconditional term thereof the giving by the claimant or plaintiff therein, to such Indemnified Party, of a release from
all liability with respect to such claim or litigation.

 

    	24

     

    

 

(d)   In order
to provide for just and equitable contribution in case indemnification is prohibited or limited by law, the Indemnifying Party,
in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result
of such losses, claims, damages or liabilities in such proportion as is appropriate to reflect the relative fault of the Indemnifying
Party and Indemnified Party in connection with the actions which resulted in such losses, claims, damages or liabilities, as well
as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined
by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of material
fact or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such Indemnifying
Party or Indemnified Party, and such party’s relative intent, knowledge, access to information and opportunity to correct
or prevent such actions; provided, however, that, in any case, (i) no Holder will be required to contribute any amount
in excess of the public offering price of all securities offered by it pursuant to such Registration Statement less all underwriting
fees and discounts and (ii) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.

 

Section 5.7.                   
Information by Holder. The Holder or Holders of Registrable Securities included in any registration shall furnish to the
Company such information regarding such Holder or Holders and the distribution proposed by such Holder or Holders as the Company
may reasonably request in writing and as shall be required in connection with any registration, qualification or compliance referred
to in this Article V.

 

Section 5.8.                   
Transfer of Registration Rights. The rights, contained in Sections 5.2 and 5.3 hereof, to cause the Company to register
the Registrable Securities, may be assigned or otherwise conveyed by DSM pursuant to a transfer not prohibited by Section 3.2.

 

    	25

     

    

 

Section 5.9.                   
Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying
any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of
this Article V.

 

Section 5.10.         
Termination of Registration Rights. In addition to any termination of this Agreement in accordance with Section 7.1 hereof,
the rights of DSM to cause the Company to register securities under Article V hereof shall terminate on the date when there no
longer remaining any Registrable Securities.

 

ARTICLE
VI

ADDITIONAL AGREEMENTS OF THE PARTIES

 

Section 6.1.                      
Protective Provisions. For so long as DSM is entitled to designate a director of the Board
pursuant to Section 2.1(a)(i) of this Agreement, without the affirmative vote of any then-serving DSM Director, the Company will
not (and, where applicable, will not permit any of its Subsidiaries to) (a) [*] or (b) other than principal and interest payments
required by the terms of such agreement (as currently in effect), use any proceeds from the transactions contemplated by the Securities
Purchase Agreement or the Tranche II Funding Amount to repay any amounts owed by the Company under that certain Loan and Security
Agreement, dated as of March 29, 2014, as amended prior to the date hereof, between the Company and Stegodon Corporation (assignee
of Hercules Technology Growth Capital, Inc.) prior to the Term Loan Maturity Date (as such term is currently defined in such agreement).

 

Section 6.2.                      
Right of First Negotiation; Toll Manufacturing Option.

 

(a)                     
The Company will not agree or commit to enter into any new agreements (or amend or otherwise modify any existing agreement to cover
any new project) with respect to any project in [*] field (the “ [*] ”), including the projects set forth on Schedule
6.2(a) attached hereto, unless the Company has first engaged in good faith negotiations with DSM with respect to such projects
for a period of at least sixty (60) days (the “Right of First Negotiation”); provided, however, that if DSM
enters into a commercial relationship with the Company with respect to any such project that obligates the Company to exclusively
develop such project with DSM, and following 24 months of the launch of such project the product development levels thereunder
do not exceed volume thresholds to be mutually agreed to by DSM and the Company within 90 days of the launch of such project, then
the Company will be released from its exclusivity obligations under such commercial relationship with DSM but the Company shall
otherwise remain bound by its other obligations thereunder.

 

(b)                    
DSM will also have an option (the “Toll Manufacturing Option”) to use the Brotas 1 or Brotas 2 facility for
toll manufacturing of DSM [*] and / or other DSM products by the Company; provided, however, that (i) such option shall
be limited to 50% of the manufacturing capacity of each such facility, (ii) (a) with respect to Brotas 1, any such products manufactured
for DSM must have a higher return to the Company relative to any alternative projects at Brotas 1 related to the manufacture,
distribution, license, sale, transfer or assignment of [*] available to the Company, as determined in good faith by the Board,
and (b) with respect to Brotas 2, any such products manufactured for DSM must have a higher return to the Company relative to
any alternative projects at Brotas 2 available to the Company, as determined in good faith by the Board.

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	26

     

    

  

(c)                     
Notwithstanding the foregoing, (i) the Toll Manufacturing Option set forth in Section 6.2(b) shall expire if the aggregate annual
cash spend by DSM (calculated for each calendar year beginning on January 1, 2018) in favor of the Company in connection with
all commercial activity with the Company, including payments for production of DSM products, license fees, exclusivity payments
and/or collaboration payments for joint development programs, is less than [*] , and (ii) the Toll Manufacturing Option set forth
in Section 6.2(b) shall not be exercisable by DSM if there are no active projects with DSM at Brotas 1 or Brotas 2 following the
date that is 36 months after the Closing.

 

Section 6.3.                      
Further Assurances; Operational Cost Savings; Foris Funding Commitment. From time to time,
at the reasonable request of any other party hereto and without further consideration, each party hereto shall execute and deliver
such additional documents and take all such further action as may be necessary or appropriate to consummate and make effective,
in the most expeditious manner practicable, the transactions contemplated by this Agreement. The Company will use reasonable best
efforts to implement operational cost/expense savings of at least [*] per annum beginning on January 1, 2018. At DSM’s request,
the Company will enforce its rights under that certain letter from Foris Ventures, LLC to the Company, dated May 6, 2017.

 

Section 6.4.                      
Tranche II Funding.  During the 90-day period following the Closing, DSM and the Company
will negotiate in good faith to mutually agree on certain terms and conditions upon which DSM shall purchase additional shares
of Preferred Stock and Warrants prior to the end of such 90-day period but after the Stockholder Approval (as such term is defined
in the Securities Purchase Agreement) has been obtained; it being acknowledged that the parties have already agreed as follows:
(a) such purchase shall be in an amount to be agreed by the Company and DSM but no less than $25 million and no more than $30 million
(such amount, the “Tranche II Funding Amount”); (b) the Company shall enter into a new securities purchase agreement
with DSM (which agreement shall be in substantially the same form as the Securities Purchase Agreement, except that (i) DSM shall
be the sole “Purchaser” thereunder, (ii) DSM’s “Subscription Amount” thereunder shall be the Tranche
II Funding Amount, and (iii) the effective price per share of the “Series B Convertible Preferred Stock” to be issued
to DSM thereunder in connection with the Tranche II Funding, without taking into account warrants to purchase shares of Common
Stock to be issued to DSM in accordance with prior discussions of the Company and DSM, shall be equal to $0.42); (c) such shares
of Preferred Stock shall have the same preferences, rights and limitations as described in the Company’s Certificate of Designation
of Preferences, Rights and Limitations of Series B 17.38% Convertible Preferred 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	27

     

    

Stock; (d) at or prior to the Tranche II Funding (as defined below)
the Company will have received at least $10 million of additional cash equity funding from other investors and at least $8 million
of additional cash debt or equity funding from an existing stockholder of the Company; (e) at the closing of the transactions contemplated
by such new securities purchase agreement (the “Tranche II Funding”); and (f) the Tranche II Funding is conditioned
upon the approval of DSM Parent’s Managing Board (in its sole discretion), (i) the Company shall enter into an amendment
to this Agreement providing for a second DSM Nominee who DSM may nominate for election to the Board but who shall not be required
to be a member of DSM Parent’s Executive Committee and (ii) the [*] License Agreement described in clause (i) of the definition
of IP License set forth in the Securities Purchase Agreement shall become effective.  Thereafter, during the 90-day period
following the closing of the Tranche II Funding (which period shall end on December 31, 2017, if earlier, the “Outside
Date”), DSM and the Company will in good faith negotiate to mutually agree on the most critical (operational) parameters
for the development of the molecule best suited to achieve the cost targets defined for [*] . In the event that the parties do
not reach agreement on such parameters prior to the Outside Date, (I) the Right of First Negotiation set forth in Section 6.2(a)
shall terminate and expire with respect to [*] only, (II) on the first anniversary of the closing of the Tranche II Funding and
each subsequent anniversary thereof, the Company will make a $5 million cash payment to DSM by wire transfer of immediately available
funds to a bank account designated by DSM in writing at least two (2) Business Days prior to each such payment date; provided that
the aggregate amount of such payments shall not exceed the Tranche II Funding Amount and (III) the Intellectual Property Escrow
Agreement described in clause (ii) of the definition of IP License set forth in the Securities Purchase Agreement shall become
effective. Following the closing of the Tranche II Funding, DSM and the Company will in good faith negotiate a development agreement
regarding each of the products listed on Schedule 6.2(a) other than [*] , it being the intention of the parties that (A) DSM will
achieve a per unit cost for such product that is competitive, but at least [*] , or as otherwise mutually agreed by the Company
and DSM, and (B) DSM will be charged only for the Company’s direct costs for development work for such product, provided
that the collaboration terms include a value sharing arrangement for the manufacturing of any product under such collaboration
by the Company for DSM. For the avoidance of doubt the prior sentence does not create an obligation to enter into a development
agreement regarding the products listed on Schedule 6.2(a) other than [*] , but rather creates an obligation to negotiate in good
faith with respect to any such agreement.

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

 

    	28

     

    

 

ARTICLE
VII 

 

TERMINATION

 

Section 7.1.                      
Termination. This Agreement shall terminate and be of no further force and effect upon and
after the Company’s consummation of a Change of Control; provided, however, that (i) such termination shall not waive or
release any party from any liability for such party’s willful breach of this Agreement occurring prior to such termination
and (ii) Section 6.2 (and, with respect thereto, Articles I and VIII) shall survive such termination and remain in full force and
effect following such termination. 

 

 

ARTICLE
VIII

MISCELLANEOUS

 

Section 8.1.                      
Entire Agreement. This Agreement (together with the Securities Purchase Agreement, the Warrants,
the IP License (as such term is defined in the Securities Purchase Agreement) and the Company’s Certificate of Designation
of Preferences, Rights and Limitations of Series B 17.38% Convertible Preferred Stock) constitutes the entire understanding and
agreement between the parties as to the matters covered herein and supersedes and replaces any prior understanding, agreement or
statement of intent, in each case, written or oral, of any and every nature with respect thereto. 

 

Section 8.2.                      
Specific Performance. The parties hereto agree that the obligations imposed on them in this
Agreement are special, unique and of an extraordinary character, and that, in the event of breach or threatened breach by any party,
damages would not be an adequate remedy and each of the other parties shall be entitled to specific performance and injunctive
and other equitable relief in addition to any other remedy to which it may be entitled, at law or in equity; and the parties hereto
further agree to waive any requirement for the securing or posting of any bond in connection with the obtaining of any such injunctive
or other equitable relief. 

 

Section 8.3.                      
Governing Law. This Agreement shall be governed by and construed in accordance with the laws
of the State of New York applicable to contracts entered into and performed entirely within such state, without regard to conflict
of laws principles.

 

Section 8.4.                      
Amendment and Waiver.

 

(a)    This
Agreement may be amended or modified, and any provision hereof may be waived, in whole or in part, at any time pursuant to an agreement
in writing executed by the Company and DSM. 

 

(b)   Any failure
by any party at any time to enforce any of the provisions of this Agreement shall not be construed a waiver of such provision or
any other provisions hereof.

 

    	29

     

    

 

Section 8.5.                      
Binding Effect. Except as otherwise expressly provided herein, the provisions hereof shall
inure to the benefit of, and be binding upon, the parties’ successors and permitted assigns.

 

Section 8.6.                      
Notices. Any and all notices or other communications or deliveries required or permitted to
be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission,
if such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this
Section prior to 6:30 p.m. (Pacific Time) on a Business Day, (b) the next Business Day after the date of transmission, if
such notice or communication is delivered via facsimile or email at the facsimile number or email address specified in this Section
on a day that is not a Business Day or later than 6:30 p.m. (Pacific Time) on any Business Day, (c) the Business Day following
the date of deposit with a nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom
such notice is required to be given. The addresses, facsimile numbers and email addresses for such notices and communications are
those set forth on the signature pages hereof, or such other address or facsimile number as may be designated in writing hereafter,
in the same manner, by any such Person.

 

Section 8.7.                      
Severability. If any portion of this Agreement shall be declared void or unenforceable by
any court or administrative body of competent jurisdiction, such portion shall be deemed severable from the remainder of this Agreement,
which shall continue in all respects valid and enforceable.

 

Section 8.8.                      
Counterparts. This Agreement may be executed in any number of counterparts, each of which
shall be deemed an original, but all of which together shall constitute a single instrument.

 

[The remainder of this page intentionally left
blank]

 

 

 

 

 

 

    	30

     

    

 

IN WITNESS WHEREOF, each of the undersigned has executed this Agreement
or caused this Agreement to be executed on its behalf as of the date first written above.

 

 

	 	 	AMYRIS, INC.
	 	 	 
	 	 	By:	/s/ John Melo
	 	 	 	Name 	John Melo
	 	 	 	Title:	President and CEO
	 	 	 	 	 
	 	 	Address for Notice:
	 	 	 
	 	 	5885 Hollis Street, Suite 100
	 	 	Emeryville, CA  94608
	 	 	 
	 	 	Facsimile No.:	 
	 	 	Email Address:	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	Attn: 	General Counsel
	 	 	 	 	 
	 	 	with a copy (which shall not constitute notice) to:
	 	 	 	 	 
	 	 	Fenwick & West LLP
	 	 	801 California Street
	 	 	Mountain View, CA 94110
	 	 	Attention:
	 	 	Email Address:

 

 

 

     

     

    

 

IN WITNESS WHEREOF, each of the undersigned has executed this Agreement
or caused this Agreement to be executed on its behalf as of the date first written above.

 

 

	 	 	DSM International
B.V.
	 	 	 
	 	 	By:	/s/ Philip Eykerman
	 	 	 	Name 	PHILIP EYKERMAN
	 	 	 	Title:	EVP CORP STRATEGY
	 	 	 	 	 
	 	 	By:	/s/ Hugh Welsh
	 	 	 	Name 	Hugh Welsh
	 	 	 	Title:	President DSM NA
	 	 	 	 	 
	 	 	Address for Notice: 	Het Overloon 1
	 	 	 	6411 TE Herleen
	 	 	 	the Netherlands
	 	 	 
	 	 	Facsimile No.:	 
	 	 	Email Address:	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	Attn: 	General Counsel
	 	 	 	 	 
	 	 	with a copy (which shall not constitute notice) to:
	 	 	 	 	 
	 	 	Latham & Watkins LLP
	 	 	330 North Wabash Ave, Suite 2800
	 	 	Chicago, Illinois 60611
	 	 	Attention:
	 	 	 
	 	 	Email Address:

 

 

 

 

     

     

    

 

Exhibit A

 

 

 

List of Competitors

 

 

 

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

 

Schedule 6.2(a)

 

 

 

Subject to those pre-existing commercial arrangements described below, as in
effect as of the date hereof, projects relating to [*].

 

 

Pre-existing commercial arrangements: The Company has pre-existing commercial
arrangements with (i) [*] and (ii) [*] .

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit 10.01

 

MODIFICATION P00004 TO THE TECHNOLOGY INVESTMENT AGREEMENT

 

Between

 

AMYRIS, INC.,

5885 Hollis Street Suite 100

Emeryville, CA 94608

 

And

 

The Defense Advanced Research Projects Agency

675 North Randolph Street

Arlington, VA 22203-2114

 

Concerning

 

Improving the Timeline for Scaling Up Molecules from Proof Of Concept to Market
Reducing Time and Cost

(Mgs TO Kgs)

 

Agreement No.: HR0011-15-3-0001

DARPA Order No.: HR0011621265

	Total Amount of the Agreement:	$	50,721,349
	Total Estimated Government Funding of the Agreement:	$	35,160,011
	Total Estimated Government Options:	$	992,168
	Contractor Share Contribution	$	15,551,338
	Funds Obligated:	$	23,324,088
	Funds Obligated by this Modification	$	0

 

 

	Recipient Identification Number/Codes:	DUNS: 185930182
	 	CAGE: 47QN9
	 	TIN: 55-0856151

 

Authority: 10 U.S.C. § 2371

 

All provisions, terms, and conditions set forth in this Agreement are applicable and
in full force and effect except as specified otherwise herein.

 

	 	 	FOR THE UNITED STATES OF AMERICA, THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY
	 	 	/s/ Michael S. Mutty
	 	 	 
	 	 	
        Michael S. Mutty

        Agreements Officer

        Contracts Management Office

	 	 	 
	 	 	6/29/2016
	 	 	(Date)

 

     

     

    

In order to create contract line item numbers tied to technical milestones to better
visibility in the Government financial payment system, identify option pricing, and correct Article V. Paragraph B. Payments for
Accomplished Payable Milestones, subparagraphs 4.c. and 4.e., the following administrative changes are made:

 

1. The Technology Investment Agreement is revised to: 1) split the total agreement value
between firm costs of $34,167,843 and option costs of $992,168, with no change in total agreement value, on the cover page and
in Article V.C. (as shown on the first page of this document); to correct Article V. Paragraph B. Payments for Accomplished Payable
Milestones, subparagraphs 4.c. and 4.e, to correct the Service Acceptor field extension to 11 and add some additional descriptive
language as shown in bold in the revised TIA, Revision 4; and revise Attachments under the Table of Contents as shown below.

 

TABLE OF CONTENTS – Revision 4

 

	ARTICLES	 	PAGE
	 	 	 
	ARTICLE I	Scope of the Agreement	3
	ARTICLE II	Term	7
	ARTICLE III	Management of the Project	10
	ARTICLE IV	Agreement Administration	11
	ARTICLE V	Obligation and Payment	12
	ARTICLE VI	Disputes	16
	ARTICLE VII	Patent Rights	17
	ARTICLE VIII	Data Rights	21
	ARTICLE IX	Foreign Access to Technology	22
	ARTICLE X	Title to and Disposition of Property	23
	ARTICLE XI	Civil Rights Act	24
	ARTICLE XII	Security	24
	ARTICLE XIII	Subcontractors	24
	ARTICLE XIV	Key Personnel	24
	ARTICLE XV	Order of Precedence	25
	ARTICLE XVI	Execution	25
	ARTICLE XVII	Applicable Law	25
	ARTICLE XVIII	Severability	25
	ARTICLE XIX	Data Sharing Plan and Status Reporting	25

 

ATTACHMENTS

 

	ATTACHMENT 1 – Revision 2	Statement of Work
	ATTACHMENT 2	Report Requirements
	ATTACHMENT 3 – Revision 4	Total Agreement Funding Plan and Payable Milestones and Corresponding Payment Schedule
	ATTACHMENT 4	Funding Schedule
	ATTACHMENT 5 – Revision 1	List of Intellectual Property Assertions by the Performer
	ATTACHMENT 6 – Revision 1	List of Property Greater than $5,000
	ATTACHMENT 7	Certifications for Agreement No. HR0011-15-3-0001

 

2. Attachment (3) Total Agreement Funding Plan and Payable Milestones and Corresponding
Payment Schedule, Revision 4 is issued to incorporate CLIN in the title with Technical Milestone and to revise the CLIN/SLIN numbers
in the CLIN/SLIN/ACRN column, as bolded, to incorporate changes tied to the CLIN breakout.

 

3. All provisions, terms, and conditions set forth in this Agreement are applicable and
in full force and effect except as specified otherwise herein.

 

     

     

    

TECHNOLOGY INVESTMENT AGREEMENT

 

BETWEEN

 

AMYRIS, INC.,

5885 HOLLIS STREET SUITE 100

EMERYVILLE, CALIFORNIA 94608

 

AND

 

THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY

675 NORTH RANDOLPH STREET ARLINGTON, VA 22203-2114

 

CONCERNING

 

IMPROVING THE TIMELINE FOR SCALING UP MOLECULES
FROM PROOF OF CONCEPT TO MARKET REDUCING TIME AND COST

(MGS TO KGS)

 

Agreement No.: HR0011-15-3-0001 – Revision 4

DARPA Order No.: HR0011518718

Total Amount of the Agreement: $50,721,349

Total Estimated Government Funding of the Agreement: $35,160,011 ($34,167,843
firm/$992,168 option)

Funds Obligated: See Article V.C

 

Authority: 10 U.S.C. § 2371

 

 

 

This Agreement is entered into between the United States of America, hereinafter
called the Government, represented by The Defense Advanced Research Projects Agency (DARPA), and AMYRIS, INC., a corporation organized
and existing under the laws of the State of Delaware with its principal place of business at 5885 Hollis Street, Suite 100, Emeryville,
California 94608 pursuant to and under U.S.

Federal law.

 

FOR AMYRIS, INCFOR THE DEFENSE ADVANCED RESEARCH
PROJECTS AGENCY

 

 

	 	 	 
	(Signature & Date)	 	(Signature & Date)
	 	 	 
	
         

         

         
	 	
        Michael S. Mutty

        Agreements Officer

         

	(Name, Title)	 	(Name, Title)
	 	 	 

 

 

     

     

    

TABLE OF CONTENTS – REVISION 3

 

 

	ARTICLES	 	PAGE
	 	 	 
	ARTICLE I	Scope of the Agreement	3
	ARTICLE II	Term	7
	ARTICLE III	Management of the Project	10
	ARTICLE IV	Agreement Administration	11
	ARTICLE V	Obligation and Payment	12
	ARTICLE VI	Disputes	16
	ARTICLE VII	Patent Rights	17
	ARTICLE VIII	Data Rights	21
	ARTICLE IX	Foreign Access to Technology	22
	ARTICLE X	Title to and Disposition of Property	23
	ARTICLE XI	Civil Rights Act	24
	ARTICLE XII	Security	24
	ARTICLE XIII	Subcontractors	24
	ARTICLE XIV	Key Personnel	24
	ARTICLE XV	Order of Precedence	25
	ARTICLE XVI	Execution	25
	ARTICLE XVII	Applicable Law	25
	ARTICLE XVIII	Severability	25
	ARTICLE XIX	Data Sharing Plan and Status Reporting	25

 

ATTACHMENTS

 

	ATTACHMENT 1 – Revision 2	Statement of Work
	ATTACHMENT 2	Report Requirements
	ATTACHMENT 3 – Revision 4	Total Agreement Funding Plan and Payable Milestones and Corresponding Payment Schedule
	ATTACHMENT 4	Funding Schedule
	ATTACHMENT 5 – Revision 1	List of Intellectual Property Assertions by the Performer
	ATTACHMENT 6 – Revision 1	List of Property Greater than $5,000
	ATTACHMENT 7	Certifications for Agreement No. HR0011-15-3-0001

 

    	 	2 of 26	 

     

    

ARTICLE I:SCOPE OF THE AGREEMENT

 

A.       Background

 

Performer is a leader in applying synthetic biology technologies
to engineer living organisms into manufacturing platforms that are able to produce a wide variety of target molecules, many of
which are impossible to produce through traditional manufacturing processes. While current technologies are highly advanced, they
suffer from a lack of integration and automation. By focusing on the same principles that made the United States the leaders in
traditional manufacturing, namely standardized engineering and efficiency gains through automation, the Performer seeks, through
funding in this Agreement, to develop a state of the art open bio-fabrication facility that will shorten the scale-up time and
cost by using biology to produce molecules. Many of these molecules are directly relevant to the DoD mission due to their unique
chemical properties that enable their use as fuels, lubricants, anti-fouling agents, antibiotics, and adhesives while also providing
building blocks for novel families of materials. DARPA’s interest in synthetic biology rises from its potential application
to manufacturing. Biological manufacturing is in its infancy and the work required to reduce the time, effort, and cost needed
to develop a new microbe is risky and at odds with the work needed to bring a product to market which is the chief goal of any
company seeking to capitalize on the technology. The Agreement supports research with a long-term perspective that will enable
academic and commercial participants to perform cutting edge research with less effort and cost than ever before. In addition to
producing molecules relevant to the DoD, the commercial opportunities are immense since virtually any molecule made through traditional
manufacturing processes can be replicated using biology as a catalyst. Although engineering cellular factories has been intermittently
successful, the cost and time required for success have been prohibitive. The Performer’s new technological approach will
develop new molecules and materials while at the same time improving efficacy and efficiency. As a result of these improvement,
the United States will reduce production time to under three years and at less than $10M per molecule while simultaneously handling
100 molecules, a 20X improvement. To achieve these innovations, the Performer will focus on technology development addressing metabolic
pathway and enzyme design, strain construction, phenotypic measurements, large-scale data analysis, and strain optimization. To
ensure success, the Performer will complement its expertise in strain engineering by partnering with companies and academic laboratories
that are leaders in their field. Upon the completion of this agreement, the capacity to perform biological engineering will far
surpass current capabilities. The United States will possess state of the art facilities for design and biomanufacturing of existing
and novel molecules and materials.

 

 

 

    	 	3 of 26	 

     

    

B.       Definitions

 

Affiliate:means, with respect to an entity, any person or entity
that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such
first entity. For purposes of this definition, “control”, “controlled by”, and “under common control
with” mean (i) the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether
through the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise or (ii)
the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of
an entity.

 

Agreement:  The body of this Agreement and Attachments 1 – 7,
which are expressly incorporated in and made a part of the Agreement.

 

Collaborators:  A third party in a contractual arrangement with the
Performer or with a Subcontractor, whether executed before or after the Effective Date, under which arrangement the Performer or
a Subcontractor has agreed to jointly research, develop and/or commercialize a technology or product with such third party and
has an “active role” in such arrangement. For the avoidance of doubt, an “active role” by the Performer
or a Subcontractor is a contractual relationship (1) that involves more than the mere transfer of intellectual property and (2)
where the Performer or a Subcontractor has a significant participation in decision making and/or funding of the activities.

 

Data:  Recorded information, regardless of form or method of recording, which
includes but is not limited to, scientific or technical data, software, trade secrets, and mask works, in each case developed or
generated by the Performer or its Subcontractors in performing the Program under this Agreement. The term “Data” does
not include financial, administrative, cost, pricing or management information.

 

Effective Date: means November 1, 2015.

 

Foreign Firm or Institution:  A firm or institution organized or existing
under the laws of a country other than the United States, its territories, or possessions. The term includes, for purposes of this
Agreement, any agency or instrumentality of a foreign government; and firms, institutions or business organizations which are owned
or substantially controlled by foreign governments, firms, institutions, or individuals.

 

Government:  The United States of America, as represented by DARPA.

 

Government Purpose Rights:  The rights to use, duplicate, or disclose
Data, in whole or in part and in any manner, for Government Purposes only, and to have or permit others to do so for Government
Purposes only.

 

Government Purpose:  Any activity in which the Government is a party,
including cooperative agreements with international or multi-national defense organizations or sales or transfers by the Government
to foreign governments or international organizations. Government Purposes include competitive procurement, but do not include
the rights to use, modify, reproduce, release, perform, display, or disclose Data for commercial purposes or authorize others to
do so.

 

Invention:  Any invention or discovery which is or may be patentable or otherwise
protectable under Title 35 of the United States Code.

 

Know-How:  All information including, but not limited to discoveries,
formulas, materials, Inventions, processes, ideas, approaches, concepts, techniques, methods, software, programs, documentation,
procedures, firmware, hardware, technical data, specifications, devices, apparatus and machines.

 

    	 	4 of 26	 

     

    

Limited Rights:  The rights to use, modify, reproduce, release, perform,
display, or disclose Data, in whole or in part, within the Government. The Government may not, without the written permission of
the Party asserting limited rights, release or disclose applicable Data outside the Government, use the applicable Data for manufacture,
or authorize the applicable Data to be used by another party, except that the Government may
reproduce, release, or disclose such Data or authorize the use or reproduction of the applicable Data by persons outside the Government
if -

 

		(i)	The reproduction, release, disclosure , or use is:

		A.	Necessary for emergency repair and overhaul; or

		B.	A release or disclosure to

1. A covered Government support contractor in performance
of its covered Government support contract for use, modification, reproduction, performance, display or release or disclosure to
a person authorized to receive Limited Rights Data; or

2. A foreign government, of such Data other than detailed
manufacturing or process Data, when use of such Data by the foreign government is in the interest of the Government and is required
for evaluational or informational purposes;

		(ii)	The recipient of the applicable Data is subject to a prohibition on the further reproduction, release, disclosure, or use of
the Data; and

		(iii)	The Performer, or its subcontractor asserting the restriction is notified of such reproduction, release, disclosure, or use.

 

Made:  Relates to any Invention means the conception or first actual
reduction to practice of such Invention.

 

Parties: The Government (represented by DARPA) and the Performer.

 

Payable Milestone: A Program-related task or tasks identified in Attachment 3
for which a corresponding payment (also identified in Attachment 3) will be made by the Government to the Performer upon the Government’s
verification, in accordance with this Agreement, that the Performer (or a Subcontractor) accomplished such task(s).

 

Performer:  AMYRIS, INC. a corporation organized and existing under the laws of
the State of

Delaware with its principal place of business at 5885 Hollis Street, Suite 100, Emeryville,
California

94608

 

Practical Application:  To manufacture, in the case of a composition
of product, to practice, in the case of a process or method, or to operate, in the case of a machine or system; and, in each case,
under such conditions as to establish that the Subject Invention is capable of being utilized and that its benefits are, to the
extent permitted by law or Government regulations, available to the public on reasonable terms. For the avoidance of doubt, the
Parties acknowledge that “Practical Application” under this Agreement may not include actual commercialization of Subject
Invention(s) hereunder because such Subject Invention(s) are likely to be Tools (e.g., it is envisioned that the Tools resulting
from the research carried out under this Agreement will later – outside of this Agreement - be used by the Performer and
its Subcontractors to develop commercial products).

 

Program: Research and development being conducted by the Performer
and its Subcontractors under this Agreement, as set forth in Article I, paragraph C and in Attachment 1, Statement of Work.

 

Property:  Any tangible personal property other than property actually
consumed during the execution of work under this Agreement.

 

    	 	5 of 26	 

     

    

Subcontractor: Those persons or entities that, per a written agreement
with the Performer, will perform certain of the Payable Milestones. As of the date of this Agreement, the Subcontractors consist
of Agilent Technologies, Inc., Arzeda Corporation, m2p-labs GmbH, Ruprecht-Karls-Universität Heidelberg, and Bruker Corporation.

 

Subject Invention:  Any Invention conceived or first actually reduced
to practice in the performance of the Program under this Agreement that is capable of use as a Tool for making or altering a genetically
modified organism; provided however, any Inventions, regardless when conceived or reduced to practice, covering a genetically modified
organism, a strain, or any compound or product made by or from an organism or strain shall not be considered “Subject Inventions”
hereunder. For the avoidance of doubt, no Inventions conceived or reduced to practice prior to the Effective Date, excluding subject
inventions conceived or first actually reduced to practice under the Amyris Living Foundries TIA HR0011-12-3-0006, shall be considered
performed “under this Agreement.”

 

Technology:  Discoveries, innovations, Know-How and Inventions, whether
patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership
accrue, including, but not limited to, patents, trade secrets, maskworks, and copyrights, developed under this Agreement.

 

Term: has the meaning set forth in Article II, paragraph A.

 

Tools: Software, analytical methods, standard operating procedures,
and workflow processes.

 

Unlimited Rights:  Rights to use, duplicate, release, or disclose Data,
in whole or in part, in any manner and for any purposes whatsoever, and to have or permit others to do so.

 

C.       Scope

 

1.       The Performer
shall perform the Program, which is intended to build an open BioFab that shortens the timeline for scaling up molecules from proof
of concept to market to two to three years, reduces the cost of such development to less than $10 million per molecule, and simultaneously
handles a hundred molecules. Success will be demonstrated by delivering 1 kg of material for 10 molecules generated by an integrated
pipeline that enables the biological production of metric tons of any subsequent molecule in two to three years. The Program shall
be carried out in accordance with the Statement of Work incorporated in this Agreement as Attachment 1. The Performer shall submit
or otherwise provide all documentation required by Attachment 2, Report Requirements.

 

2.       The Performer
shall be paid for each Payable Milestone accomplished in accordance with the Schedule of Payments and Payable Milestones set forth
in Attachment 3 and the procedures of Article V. The Schedule of Payments and Payable Milestones set forth in Attachment 3 may
be revised or updated in accordance with Article III, subject to mutual agreement of the Parties.

 

3.       The Government and the
Performer estimate that the Statement of Work for this Agreement can only be accomplished with the Performer’s provision
during the Term of the “Performer Contribution”, as detailed in the Total Agreement Funding Plan set forth in Attachment
3 and the Funding Schedule set forth in Attachment 4. The Total Agreement Funding Plan and the Funding Schedule may be revised
or updated in accordance with Article III, subject to mutual agreement of the Parties. The Performer intends and, by entering into
this Agreement, undertakes to cause the Performer Contribution to be provided. However, if either the Government or the Performer
is unable to provide its respective funding (in the case of the Government) or the Performer Contribution (in the case of the Performer)
for the Program, the other Party

 

    	 	6 of 26	 

     

    

may reduce its funding or Performer Contribution, whichever is applicable to it, for
the Program by a proportional amount. Throughout the Term, the Parties, through the Performer’s routine reports to the Government,
will monitor the Performer’s satisfaction of the Performer Contribution and will promptly address, in good faith, any divergence
or shortfall in the final Performer Contribution amount anticipated by the Performer (e.g., the Performer purchases Property for
the Program at a price significantly cheaper than what was anticipated when establishing the Performer Contribution) and its effect,
if any, on the Government’s funding obligation under this Agreement.

 

D.       Goals / Objectives

 

1.       The goal of
this Agreement is for the Performer to investigate and build a BioFab that scales up molecules from proof of concept to market
in less time and at less cost, as described under Scope above. The goal is to accomplish this by incorporating radical innovations
into key modules at each stage of the Design-Build-Test-Learn cycle as described in detail Amyris Proposal “Mgs to Kgs”
dated February 3, 2015. The modules will be interdependent and align within an integrated pipeline. The foundation is a set of
measurement technologies with various levels of risk. In addition to new algorithms for pathway prediction, data analysis and hypothesis
generation, the BioFab’s testing and optimization of up to 450 molecules from a large metabolic space will require a paradigm
shift from a high-throughput, single-molecule screening platform to a high throughput, molecule-agnostic screening platform that
is predictive of performance to a large scale. To address the gaps in throughput, quality and scale, a testing platform that utilizes
a tiered approach to promote strains will be developed. Although individual tiers exist in some form at various institutions and
companies (including at the Performer), there is not a single platform that has managed to encompass all of them into a single
pipeline at the proposed scale.

 

2.       The Government
will have continuous involvement with the Performer. The Government will also obtain access to research results and certain rights
in Data and Subject Inventions pursuant to Articles VII and VIII. Government and the Performer are bound to each other by a duty
of good faith and best research effort in achieving the goals of the Program.

 

3.       This Agreement
is an "other transaction" pursuant to 10 U.S.C. § 2371. The Parties agree that the principal purpose of this Agreement
is for the Government to support and stimulate the Performer to provide its best effort in advanced research and technology development
and not for the acquisition of property or services for the direct benefit or use of the Government. The Performer will be paid
a fixed amount for each Payable Milestone accomplished in accordance with the Payable Milestones and Corresponding Payment Schedule
set forth in Attachment 3 and the procedures of Article V. The Parties agree that the amount payable to Performer for an accomplished
Payable Milestone will be unaffected by whether Performer ends up expending more or less effort to accomplish such Payable Milestone
than the Parties assumed would be required to accomplish it. This Agreement is not intended to be, nor shall it be construed as,
by implication or otherwise, a partnership, a corporation, or other business organization.

 

ARTICLE II: TERM

 

A.       Term of this Agreement

 

The Program commences upon the Effective Date and continues
for forty-eight (48) months, unless extended as described in paragraph C below, (the “Term”) and is split into three
development and operational phases described below and depicted in the table:

 

“Dev” – in the first twenty-four months, the initial set of
strain designs and testing will be generated using existing infrastructure and processes, while simultaneously developing the new
technology platforms simultaneously;

 

    	 	7 of 26	 

     

    

“DevOps” – newly developed technology platforms will be transferred
to pipeline operations as part of the beta-testing transition process;

 

“Ops” – once the technology transfer is completed, the new
technologies will be part of standard operations.

 

If all Government funds committed for the Program and the
Performer Contribution are expended prior to the expiration of the Term, the Parties have no obligation to continue performance
of the Program and may elect to cease development at that point.

 

Provisions of this Agreement, which, by their express terms
or by necessary implication, apply for periods of time other than specified herein, shall be given effect, notwithstanding this
Article.

 

 

 

 

 

 

 

 

 

 

 

    	 	8 of 26	 

     

    

[*]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

    	 	9 of 26	 

     

    

B.       Termination Provisions

 

Subject to a reasonable determination that the Program will
not produce beneficial results commensurate with the expenditure of resources, either Party may terminate this Agreement by written
notice to the other Party, provided that such written notice is preceded by consultation between the Parties. In the event
of a termination of the Agreement under this paragraph B, it is agreed that disposition of Data shall be in accordance with the
provisions set forth in Article VIII, Data Rights. The Government and the Performer will negotiate in good faith a reasonable and
timely adjustment of all outstanding issues between the Parties as a result of termination under this paragraph B. Failure of the
Parties to agree to a reasonable adjustment will be resolved pursuant to Article VI, Disputes. The Government has no obligation
to pay the Performer beyond the last completed and paid Payable Milestone if the Performer decides to terminate under this paragraph
B. For the avoidance of doubt, any termination under this paragraph B by either Party does not require repayment by the Performer
of any Payable Milestone amounts already received by the Performer.

 

C.       Extending the Term

 

The Parties may extend, by mutual written agreement, the
Term if funding availability and research opportunities reasonably warrant. Any extension shall be formalized through modification
of the Agreement by the DARPA Agreements Officer and the Performer’s Administrator.

 

ARTICLE III: MANAGEMENT OF THE PROJECT 

 

A.       Management and Program Structure

 

The Performer shall be responsible for the overall technical
and program management of the Program, and technical planning and execution shall remain with the Performer. The DARPA Agreements
Officer’s Representative, in consultation with the DARPA Program Manager or DARPA management, shall provide recommendations
to Program developments and technical collaboration and be responsible for the review and verification of the Payable Milestones.

 

B.       Program Management Planning Process

 

Program planning will consist of an Annual Program Plan with inputs
and review from the Performer and DARPA management, containing the detailed schedule of research activities and Payable Milestones.
The Annual Program Plan will consolidate quarterly adjustments in the Program’s research schedule, including revisions/modification
to Payable Milestones.

 

1.       Initial
Program Plan: The Performer will follow the initial program plan that is contained in the Statement of Work, Attachment 1, and
in the Payable Milestones and Corresponding Payment Schedule, Attachment 3.

 

2.       Overall Program Plan Annual
Review

 

(a)       The Performer,
with DARPA Agreements Officer’s Representative review, in consultation with the DARPA Program Manager or DARPA management,
will prepare an overall Annual Program Plan in the last month of each Agreement year (i.e., October). The Annual Program
Plan will be presented and reviewed at an annual site review, to be held within the sixty (60) days of each subsequent Agreement
year, which will be attended by the Performer’s Key Personnel (as defined in Article XIV), the DARPA Agreements Officer’s
Representative, senior DARPA management (as appropriate), and other DARPA program managers and personnel (as appropriate). The
Performer, with DARPA participation and review,

    	 	10 of 26	 

     

    

will prepare a final Annual Program Plan following such annual site review
as more fully described in Attachment 2, Report Requirements.

 

(b)       The Annual
Program Plan provides a detailed schedule of the Program’s research activities, commits the Performer to use its best efforts
to meet specific performance objectives, includes forecasted expenditures and describes the Payable Milestones. The Annual Program
Plan will consolidate all prior adjustments in the Program’s research schedule, including revisions/modifications to the
Payable Milestones. Recommendations for changes, revisions or modifications to the Agreement which result from this annual review
process shall be made in accordance with the provisions of Article III, paragraph C.

 

C.        Modifications

 

1.       As a result of
the Parties’ meetings (in person or videoconference) or annual reviews or at any other time during the Term, the Program’s
research progress or results or other changes in circumstances (e.g., availability of required materials or equipment from external
vendors, legal freedom to operate, etc.) may indicate that a change in the Statement of Work and/or the Payable Milestones would
be beneficial to Program’s objectives. Recommendations for modifications, including justifications to support any changes
to the Statement of Work and/or the Payable Milestones, will be documented in a letter and submitted by the Performer to the DARPA
Agreements Officer’s Representative with a copy to the DARPA Agreements Officer. This documentation letter will detail the
technical, chronological, and financial impact of the proposed modification to the Program. The Performer shall approve any Agreement
modification. The Government is not obligated to pay for additional or revised Payable Milestones until the Payable Milestones
and Corresponding Payment Schedule, Attachment 3, is formally revised by the DARPA Agreements Officer and made part of this Agreement.

 

2.       The DARPA Agreements
Officer’s Representative shall be responsible for the review and verification of any recommendations to revise or otherwise
modify the Agreement, the Statement of Work, the Payable Milestones and Corresponding Payment Schedule, or any other proposed changes
to the terms and conditions of this Agreement.

 

3.       For
minor or administrative Agreement modifications (e.g., changes in the paying office or appropriation data, changes to Government
or the Performer’s personnel identified in the Agreement, etc.), no signature is required by the Performer.

 

ARTICLE IV: AGREEMENT ADMINISTRATION

 

Unless otherwise provided in this Agreement, approvals permitted
or required to be made by the Government may be made only by the DARPA Agreements Officer. Administrative and contractual matters
under this Agreement shall be referred to the following representatives of the Parties:

 

A.          
Government Points of Contact:

 

DARPA Agreements Officer:

  

DARPA Program Manager:

  

DARPA Agreements Officer’s Representative (AOR):

  

    	 	11 of 26	 

     

    

DARPA Administrative Agreements Officer (AAO):

 

 

DARPA Assistant Director, Program Management (ADPM)

 

 

B.       Performer Points of Contact

 

Administrator:

, Program Manager, R&D,

 

Contracting:

, General Counsel,

 

Program Manager:

, PI,

 

BioAnalytics Group Leader:

, Co-PI,

 

Each Party may change its representatives named in this Article by written notification
to the other Party. The Government will effect the change as stated in Article III, C.3 above.

 

ARTICLE V: OBLIGATION AND PAYMENT

A.Obligation

1.       The Government’s
liability to make payments to the Performer is limited to only those funds obligated under the Agreement or by modification to
the Agreement. The Government may obligate funds to the Agreement incrementally.

 

2.       If modification
of a Payable Milestone becomes necessary in performance of this Agreement, pursuant to Article III, paragraph C, the DARPA Agreements
Officer and the Performer’s Administrator shall execute a revised Payable Milestones and Corresponding Payment Schedule consistent
with the then current Annual Program Plan.

 

B.       Payments for Accomplished Payable Milestones

 

1.       The Performer
has, and agrees to maintain, an established accounting system, which complies with Generally Accepted Accounting Principles and
the requirements of this Agreement and shall ensure that appropriate arrangements have been made for receiving, distributing and
accounting for all funding. An acceptable established accounting system is one in which all cash receipts and disbursements are
controlled and documented properly.

 

2.       Once the Performer
accomplishes a Payable Milestone, the Performer may seek payment from the Government of the corresponding payment amount in the
Payable Milestones and Corresponding Payment Schedule in Attachment 3. The Performer shall document the accomplishment of such
Payable Milestone by submitting or otherwise providing the Payable Milestones Report required by Attachment 2, Part F. After written
verification of the accomplishment of such Payable Milestone by the DARPA Agreements Officer’s Representative and approval
by the DARPA Agreements Officer, the associated invoice will

    	 	12 of 26	 

     

    

be submitted to the payment office via Wide Area Workflow (“WAWF”),
as detailed in subparagraph B.6 of this Article. If a Payable Milestone is composed of more than one task (e.g., Payable
Milestones 2, 6, 7, etc.), all such tasks in such Payable Milestone must be fully accomplished before the Performer may
seek payment for such Payable Milestone. However, if a task in a single task Payable Milestone (or all of the tasks in a multi-task
Payable Milestone) cannot be completed by the applicable Milestone (MS) Month set forth in Attachment 3, the Performer will document
such event in its Monthly Technical Status Report, and the Parties will execute a contract modification to incorporate required
changes in Attachment 3, and in Attachments 1 and 4, as applicable. For clarity, the “MS Month” column set forth in
Attachment 3 sets forth the Parties’ good faith estimate of the date by which a Payable Milestone will be accomplished, but
it is not a deadline for accomplishing the applicable Payable Milestone. In addition, missing the MS Month does not prevent the
Performer from subsequently accomplishing the applicable Payable Milestone and has no effect on the corresponding payment amount
in Attachment 3 once accomplished.

 

If deemed necessary by the DARPA Agreements Officer, payment
approval for the final Payable Milestone will be made after reconciliation of actual Government funding for the Program with the
actual Performer Contribution amount. While there will be this final Government reconciliation and accounting of the Performer
Contribution amount, the Parties agree that the quarterly accounting of the Performer Contribution, as reported in the quarterly
Business Status Report submitted in accordance with Attachment 2, will not, nor is it necessarily intended or required to, uniformly
or proportionally track or match the estimated schedule of the Performer Contribution set forth in either Attachments 3 or 4.

 

3.       Subject to
change only through written Agreement modification, payment shall be made to the address of the Performer’s Administrator
set forth below.

 

AMYRIS, INC., 5885 Hollis Street, Suite 100, Emeryville, California
94608

 

4.       Payments will
be made by the cognizant Defense Agencies Financial Services office, as indicated below, within thirty (30) calendar days of an
accepted invoice in WAWF. WAWF is a secure web-based system for electronic invoicing, receipt and acceptance. The WAWF application
enables electronic form submission of invoices, government inspection, and acceptance documents in order to support DoD’s
goal of moving to a paperless acquisition process. Authorized DoD users are notified of pending actions by e-mail and are presented
with a collection of documents required to process the contracting or financial action. It uses Public Key Infrastructure (“PKI”)
to electronically bind the digital signature to provide non-reputable proof that the user (electronically) signed the document
with the contents. Benefits include online access and full spectrum view of document status, minimized re-keying and improving
data accuracy, eliminating unmatched disbursements and making all documentation required for payment easily accessible.

 

The Performer is required to utilize the WAWF system when
processing invoices and receiving reports under this Agreement. The Performer shall (i) ensure an Electronic Business Point of
Contact is designated in Central Contractor Registration at http://www.ccr.gov and (ii)
register to use WAWF–RA at the https://wawf.eb.mil site, within ten (10) calendar
days after award of this Agreement. Step by step procedures to register are available at the https://wawf.eb.mil
site. The Performer is directed to use the “2-in-1” format when processing invoices.

 

a.       For the Issue By DoDAAC
enter HR0011

b.       For the Admin DoDAAC and Ship To fields, enter S0507A.

c.       For the Service
Acceptor field, enter HR0011, Extension 01.

d.       Leave the
Inspect by DoDAAC, Ship From Code DoDAAC and LPO DoDAAC fields blank unless otherwise directed by the DARPA Agreements Officer
or DARPA Administrative Agreements Officer.

    	 	13 of 26	 

     

    

e.       The following guidance
is provided for invoicing processed under this Agreement through WAWF:

 

•The DARPA Agreements Officer’s Representative identified
at Article IV "Agreement Administration" shall continue to formally inspect and accept the deliverable Payable Milestone
reports. To the maximum extent practicable, the DARPA Agreements Officer’s Representative shall review the Payable Milestone
report(s) and either: 1) provide a written notice of rejection to the Performer which includes feedback regarding deficiencies
requiring correction or 2) written notice of acceptance to the DARPA Administrative Agreements Officer, DARPA Program Manager and
DARPA Agreements Officer.

 

•Acceptance within the WAWF system shall be performed by the
DARPA Agreements Officer upon receipt of a confirmation email, or other form of transmittal, from the DARPA Agreements Officer’s
Representative.

 

•The Performer shall send an email notice to the DARPA Agreements
Officer’s Representative and DARPA Agreements Officer upon submission of an invoice in WAWF (this can be done from within
WAWF).

 

•Payments shall be made by DFAS-CO/WEST (HQ0339)

 

•The Performer agrees, when entering invoices entered in WAWF
to utilize the CLINs associated with each Payable Milestone as delineated at Attachment 3. The description of the CLIN shall include
reference to the associated technical milestone number and task along with other necessary descriptive information.
The Performer agrees that the Government may reject invoices not submitted in accordance with this provision.

 

Note for DFAS: The Agreement shall be entered into the DFAS system by CLIN
– Milestone association as delineated at Attachment 3. The Agreement is to be paid out by CLIN – Milestone association.
Payments shall be made using the CLIN (MS)/ACRN association as delineated at Attachment 3.

 

5.       Payee Information:
As identified at Central Contractor Registration.

 

•Cage Code: 47QN9

•DUNS: 185930182

•TIN: 55-0856151

 

6.       Financial Records
and Reports: The Performer shall maintain adequate records to account for accomplishment of all Payable Milestones for which payment
is received by the Performer under this Agreement and shall maintain adequate records to account for the Performer Contribution
provided under this Agreement. Upon completion or termination of this Agreement, whichever occurs earlier, the Performer’s
Administrator shall furnish to the DARPA Agreements Officer a copy of the Final Report required by Attachment 2, Part E. The Performer’s
relevant financial records are subject to examination or audit on behalf of DARPA by the Government for a period not to exceed
three (3) years after expiration or earlier termination of the Term. The DARPA Agreements Officer or designee shall have direct
access to sufficient records and information of the Performer to ensure accomplishment of the Payable Milestones for which payment
was received by the Performer under this Agreement and satisfaction of the Performer Contribution under this Agreement. Such audit,
examination, or access shall be performed during business

    	 	14 of 26	 

     

    

hours on business days upon reasonable, prior written notice and shall be subject
to the security requirements of the audited party. For clarity, where the labor component of the Performer Contribution is based
upon a fixed price hourly commercial rate(s) documented in a contract (e.g., GSA Schedule contract), the examination or audit of
the labor component of such costs shall be limited to a review of hours worked and shall not include a review of the rates.

 

C.       Agreement Value, Agreement Funding and
Accounting and Appropriation Data

 

Agreement Value

 

Total Amount of the Agreement: $50,721,349

Total Estimated Government Funding of the Agreement: $35,160,011 ($34,167,843 firm/$992,168
option)

 

Agreement Funding

	TIA Award	$ 6,035,686
	P00002	$10,639,695
	P00003	$ 6,648,707
	Total Funds Obligated	$23,324,088

 

 

Accounting and Appropriation Data

 

TiA Award

CLIN/SLIN/ACRN: 0001/01/AA

LOA: 012199 097 0400 000 N 20152016 D 1320 BLTM66 2015.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $6,035,686

 

P00002

CLIN/SLIN/ACRN: 0001/01/AB

LOA: 012199 097 0400 000 N 20162017 D 1320 BLTM66 2016.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $10,639,695

 

P00003

CLIN/SLIN/ACRN: 0001/01/AB

LOA: 012199 097 0400 000 N 20162017 D 1320 BLTM66 2016.MBT-02.CORE.A DARPA 255

FUNDING AMOUNT: $6,648,707

 

    	 	15 of 26	 

     

    

ARTICLE VI: DISPUTES

 

A.       General

 

The Parties shall communicate with one another in good faith and in a timely
and cooperative manner when raising issues under this Article.

 

B.       Dispute Resolution Procedures

 

1.       Any dispute, disagreement,
or misunderstanding between the Government and the Performer concerning questions of fact or law arising from or in connection
with this Agreement, and, whether or not involving an alleged breach of this Agreement, may be raised only under this Article.

 

2.       Whenever disputes,
disagreements, or misunderstandings arise, the Party aggrieved by such dispute, disagreement, or misunderstanding shall provide
written notice to the other Party involved identifying the matter in dispute and inviting the other Party involved in the dispute
to attempt to resolve the issue(s) involved by discussion and mutual agreement as soon as practicable. If the aggrieved Party does
not provide the notification made under subparagraph B.3 of this Article within three (3) months of becoming aware of the dispute,
disagreement, or misunderstanding, then such dispute, disagreement, or misunderstanding will not constitute the basis for relief
under this Article unless the Director of DARPA in the interests of justice waives this requirement.

 

3.       Failing resolution
by mutual agreement described above, the aggrieved Party shall document the dispute, disagreement, or misunderstanding by notifying
the other Party (through the DARPA Agreements Officer or the Performer’s Administrator, as the case may be) in writing of
the relevant facts, identify unresolved issues, and specify the clarification or remedy sought. Within five (5) business days after
providing such notice to the other Party, the aggrieved Party may, in writing, request a joint decision by the DARPA Senior Procurement
Executive and a senior executive (no lower than Vice President, Legal) appointed by the Performer. The other Party shall submit
a written position on the matter(s) in dispute within thirty (30) calendar days after being notified in writing that a joint decision
has been requested regarding the dispute, disagreement, or misunderstanding. The DARPA Senior Procurement Executive and the Performer’s
senior executive shall conduct a review of the matter(s) in dispute and render a decision in writing within thirty (30) calendar
days of receipt of such other Party’s written position. Any such joint decision is final and binding.

 

4.       In the absence
of a joint decision, upon written request to the Director of DARPA, made within thirty (30) calendar days of the expiration of
the time for a joint decision under subparagraph B.3 above, the dispute, disagreement, or misunderstanding shall be further reviewed.
The Director of DARPA may elect to conduct this review personally or through a designee or jointly with a senior executive (no
lower than Vice President, Legal) appointed by the Performer. Following the review, the Director of DARPA or designee will resolve
the issue(s) and notify the Parties in writing. Such resolution is not subject to further administrative review and, to the extent
permitted by law, shall be final and binding.

 

C.       Limitation of Damages

 

Claims for damages of any nature whatsoever pursued under
this Agreement shall be limited to direct damages only up to the aggregate amount of Government funding disbursed as of the time
the dispute arises. In no event shall the Government be liable for claims for consequential, punitive, special and incidental damages,
claims for lost profits, or other indirect damages.

 

    	 	16 of 26	 

     

    

ARTICLE VII: PATENT RIGHTS

 

A.       Allocation of Principal Rights

 

1. Unless the Performer shall have notified DARPA (in accordance
with subparagraph B.2 below) that the Performer does not intend to retain title, the Performer shall retain the entire right, title,
and interest throughout the world to each Subject Invention consistent with the provisions of this Article and 35 U.S.C. §
202. With respect to any Subject Invention in which the Performer retains title, the Government shall have a nonexclusive, nontransferable,
irrevocable, paid-up license to practice or have practiced on behalf of the Government the Subject Invention throughout the world.

 

2. With regard to Inventions made under this Agreement that are not
Subject Inventions, i.e. Inventions relating to genetically modified organisms, strains, or any compounds or products made by or
from such organisms or strains that are conceived or first actually reduced to practice in the performance of the Program, the
Government retains a right to request from Performer a nonexclusive, nontransferable, irrevocable license, on fair and reasonable
terms, to such Inventions to have such Inventions practiced on behalf of the Government throughout the world. The Government will
provide Performer with written notice identifying the specific Invention to which it is requesting such license. Prior to granting
such license, the Parties agree to negotiate in good faith fair and reasonable terms under which the Performer would be the exclusive
supplier/manufacturer to the Government of the desired compound or product under the Government’s license. Upon agreement
of such fair and reasonable terms between the Performer and the Government, the Performer shall grant the Government the nonexclusive
license described above to such identified Inventions. In the event that no agreement is reached between Performer and Government
with regard to said fair and reasonable terms on Performer’s supply/manufacturing rights, Performer shall nonetheless grant
the Government a nonexclusive, nontransferable, irrevocable license, on fair and reasonable terms, to such Inventions to have such
Inventions practiced on behalf of the Government throughout the world. Failure to reach agreement on fair and reasonable terms
will be resolved in accordance with Article VI. Disputes.

 

3. Notwithstanding anything to the contrary in subparagraph A.2 above,
the Parties agree that any license to the Government to any Inventions made under this Agreement that are not Subject Inventions
expressly excludes any and all rights to make, have made, use, sell, offer for sale, or import any compound or product as, or in,
a Flavor or Fragrance, unless the Parties reasonably determine that a national security interest requires the Government to use
such compound or product as, or in, a Flavor or Fragrance, in which case subparagraph A.2 will also be applicable to such use.
As used in this paragraph, “Flavor” means an ingredient(s) whose intended or primary functionality (individually or
as part of a blend with auxiliary materials) is to impart, modify, boost or enhance a desirable taste, flavor or sensation, or
to conceal, modify or minimize an undesirable taste, flavor or sensation, in materials designed for consumption (including food,
beverages, drugs, tobacco and any animal feed). As used in this paragraph, “Fragrance” means an ingredient(s) whose
intended or primary functionality (individually or as part of a blend with auxiliary materials) is to impart, modify, boost or
enhance a desirable scent or odor or to conceal, modify or minimize an undesirable scent or odor, in consumer and industrial grade
products.

 

B.       Invention Disclosure, Election
of Title, and Filing of Patent Application

 

1.       The Performer
shall disclose each Subject Invention to DARPA within four (4) months after the inventor discloses it in writing to Performer’s
personnel responsible for patent matters or, in the case of no internal writing from the inventor, within two (2) months after
Performer files a provisional application for it; provided however, that in the event the Performer does not file a provisional
application, Performer shall disclose the Subject Invention to the Government within two (2) months of determining that a particular
set of experiments and or data qualify as a Subject Invention. The disclosure to the Government shall be in the

    	 	17 of 26	 

     

    

form of a written report and shall identify the Agreement under which the Subject
Invention was Made and the identity of the inventor(s). It shall be sufficiently complete in technical detail to convey a clear
understanding to the extent known at the time of the disclosure, of the nature, purpose, operation, and the physical, chemical,
biological, or electrical characteristics of the Subject Invention. The disclosure shall also identify any publication, sale,
or public use of the Subject Invention and whether a manuscript describing the Subject Invention has been submitted for publication
and, if so, whether it has been accepted for publication at the time of disclosure. The Performer shall also submit to the Government
an annual listing of Subject Inventions.

 

2.       If the Performer
determines that it does not intend to retain title to any such Subject Invention, the Performer shall notify the Government, in
writing, within eight (8) months of disclosure to DARPA. However, in any case where publication, sale, or public use has initiated
the one (1)-year statutory period wherein valid patent protection can still be obtained in the United States, the period for such
notice may be shortened by DARPA to a date that is no more than sixty (60) calendar days prior to the end of the statutory period.

 

3.       The Performer
shall file its initial patent application on a Subject Invention to which it elects to retain title within one (1) year after election
of title or, if earlier, prior to the end of the statutory period wherein valid patent protection can be obtained in the United
States after a publication, or sale, or public use. The Performer may elect to file patent applications in additional countries
(including the European Patent Office and the Patent Cooperation Treaty) within either: (i) ten (10) months of the corresponding
initial patent application; or (ii) six (6) months from the date permission is granted by the Commissioner of Patents and Trademarks
to file foreign patent applications where such filing has been prohibited by a secrecy order.

 

4.       Requests
for extension of the time for disclosure, election, and filing under Article VII, paragraph B, may, at the discretion of DARPA,
and after considering the position of the Performer, be granted.

 

C.       Conditions When the Government
May Obtain Title

 

Upon DARPA’s written request, the Performer shall convey
title to any Subject Invention to DARPA under any of the following conditions:

 

1.       If the Performer
fails to disclose or elects not to retain title to the Subject Invention within the times specified in paragraph B of this Article;
provided, that DARPA may request title only within sixty (60) calendar days after learning of: (i) the failure of the Performer
to disclose; or (ii) Performer’s election not to retain title, in each case within the specified times.

 

2.       In those countries
in which the Performer fails to file patent applications within the times specified in paragraph B of this Article; provided, that
if the Performer has filed a patent application in a country after the times specified in paragraph B of this Article, but prior
to its receipt of the written request by DARPA, the Performer shall continue to retain title to the Subject Invention in that country;
or

 

3.       In any country
in which the Performer decides not to continue the prosecution of, to pay the maintenance fees on, or defend a reexamination of
or opposition proceedings on, a patent application or patent on a Subject Invention.

 

D.       Minimum Rights to the Performer
and Protection of the Performer’s Right to File

 

1.       The Performer
shall retain a nonexclusive, royalty-free, paid-up license throughout the world in each Subject Invention to which the Government
obtains title under paragraph C of this Article, except if the

    	 	18 of 26	 

     

    

Performer fails to disclose the Subject Invention within the times specified
in paragraph B of this Article. The Performer’s license to such Subject Invention extends to the Performer’s Affiliates
and Collaborators, if any, and includes the right to grant sublicenses of the same scope to the extent that the Performer was legally
obligated to do so at the time the Agreement was awarded. The license is transferable only with the approval of DARPA, except as
noted above regarding Affiliates and Collaborators of Performer or when transferred to the successor of that part of the Performer’s
business to which the Subject Invention pertains. DARPA approval for a license transfer requiring DARPA approval shall not be unreasonably
withheld or delayed.

 

2.       The Performer’s
license in subparagraph D.1 of this Article may be revoked or modified by DARPA to the extent necessary to achieve expeditious
Practical Application of the Subject Invention pursuant to an application for an exclusive license submitted consistent with appropriate
provisions at 37 CFR Part 404. This license shall not be revoked in that field of use or the geographical areas in which the Performer
continues to practice the general technology developed hereunder in pursuit of commercial goals, including the goal of making the
products derived from such platforms reasonably accessible to the public.

 

3.       Before revocation
or modification of the Performer’s license in subparagraph D.1 of this Article, DARPA shall furnish the Performer a written
notice of its intention to revoke or modify the license, and the Performer shall be allowed thirty (30) calendar days (or such
other time as may be authorized for good cause shown) after the notice to show cause why the license should not be revoked or modified.

 

E.       Action to Protect the Government’s
Interest

 

1.       The Performer
agrees to execute or to have executed and promptly deliver to DARPA all instruments necessary to: (i) establish or confirm the
rights the Government has throughout the world in those Subject Inventions to which the Performer elects to retain title; and (ii)
convey title to DARPA when requested under paragraph D of this Article and to enable the Government to obtain patent protection
throughout the world in that Subject Invention.

 

2.       The Performer
agrees to require, by written agreement, its employees, other than clerical and non-technical employees, to disclose promptly in
writing to personnel identified as responsible for the administration of patent matters and in a format suggested by the Performer
each Subject Invention Made under this Agreement in order that the Performer can comply with the disclosure provisions of paragraph
B of this Article. The Performer shall instruct employees, through employee agreements or other suitable educational programs,
on the importance of reporting Subject Inventions in sufficient time to permit the filing of patent applications prior to U.S.
or foreign statutory bars.

 

3.       The Performer
shall notify DARPA of any decisions not to continue the prosecution of, pay maintenance fees for, or defend in a reexamination
or opposition proceedings on a Subject Invention patent application or patent, in any country, not less than thirty (30) calendar
days before the expiration of the response period required by the relevant patent office.

 

4.       The Performer
shall include, within the specification of any United States patent application and any patent issuing thereon covering a Subject
Invention, the following statement: “This invention was made with Government support under Agreement HR0011-15-3-0001, awarded
by DARPA. The Government has certain rights in the invention.”

 

F.       Lower Tier Agreements

 

The Performer shall include this Article VII, suitably modified
to identify the Parties and, as applicable, Subcontractors, in all subcontracts or lower tier agreements, regardless of tier,
for experimental, developmental, or research work under the Program.

 

    	 	19 of 26	 

     

    

G.       Reporting on Utilization of Subject
Inventions

 

1.       Pursuant to Attachment
2, the Performer agrees to submit, during the Term, an annual report on the general subject matter research at Performer or its
Collaborators, licensees or assignees in connection with utilization of a Subject Invention or on efforts at obtaining such utilization
that is being made by the Performer or its Collaborators, licensees or assignees. Such reports shall include information regarding
the general fields of potential products where such Subject Inventions may ultimately assist in commercial sales. The Performer
also agrees to provide additional reports as may be requested by DARPA in connection with any march-in proceedings undertaken by
DARPA in accordance with paragraph I of this Article. Consistent with 35 U.S.C. § 202(c) (5), DARPA agrees it shall not disclose
such information to persons outside the Government without permission of the Performer.

 

2.       All required reporting
shall be accomplished, to the extent possible, using the iEdison reporting website: https://s-edison.info.nih.gov/iEdison/.
To the extent any such reporting cannot be carried out by use of i-Edison, reports and communications shall be submitted to the
DARPA Agreements Officer and DARPA Administrative Agreements Officer.

 

H.       Preference for American Industry

 

Notwithstanding any other provision of this clause, the Performer
agrees that it shall not grant to any person the exclusive right to use or sell any Subject Invention in the United States or Canada
unless such person agrees that any product embodying the Subject Invention or produced through the use of the Subject Invention
shall be manufactured substantially in the United States or Canada, except when such rights are in connection with a Collaborator.
However, in individual cases, the requirements for such an agreement beyond what is contemplated herein may be waived by DARPA
upon a showing by the Performer: (1) that reasonable but unsuccessful efforts have been made to grant licenses on similar terms
to potential licensees that would be likely to manufacture substantially in the United States; or (2) that, under the circumstances,
domestic manufacture is not commercially feasible.

 

I.       March-in Rights

 

The Performer agrees that, with respect to any Subject Invention
in which it has retained title, DARPA has the right to require the Performer, an assignee, or exclusive licensee of a Subject Invention
to grant a non-exclusive license to a responsible applicant or applicants, upon terms that are reasonable under the circumstances,
and if the Performer, assignee, or exclusive licensee refuses such a request, DARPA has the right to grant such a license itself
if DARPA determines that:

 

1.       Such action is
necessary because the Performer, assignee, or exclusive licensee has not taken effective steps, consistent with the intent of this
Agreement, to achieve Practical Application of the Subject Invention;

 

2.       Such action is
necessary to alleviate health or safety needs which are not reasonably satisfied by the Performer, assignee, or exclusive licensee;

 

3.       Such action is
necessary to meet requirements for public use and such requirements are not reasonably satisfied by the Performer, assignee, or
exclusive licensee; or

 

4.       Such action is
necessary because the agreement required by paragraph I of this Article has not

 

    	 	20 of 26	 

     

    

been obtained or waived or because a licensee of the exclusive right to use or
sell any Subject Invention in the United States is in breach of such agreement.

 

ARTICLE VIII: DATA RIGHTS

 

A.       Allocation of Principal Rights

 

1.       This Agreement
shall be performed with mixed Government and Performer funding. The Parties agree that in consideration for Government funding,
the Performer intends to reduce to Practical Application Subject Invention(s) developed under this Agreement.

 

2.       The Performer
agrees to retain and maintain in good condition, until two (2) years after completion or termination of this Agreement, all Data
necessary to achieve Practical Application of Subject Invention(s).

 

3.       In the event of
exercise of the Government’s “March-in Rights” as set forth under Article VII or in this subparagraph, the Performer
agrees that, with respect to Data necessary to achieve Practical Application of the applicable Subject Invention(s), the Government
has the right to require the Performer to deliver, within sixty (60) calendar days from the date of the written request and at
no additional cost to the Government, all such Data to the Government in accordance with its reasonable directions if the Government
determines that:

 

(a)       Such action is
necessary because the Performer, assignee, or exclusive licensee has not taken effective steps, consistent with the intent of this
Agreement, to achieve Practical Application of the Subject Invention(s) developed during the performance of this Agreement;

 

(b)       Such action is
necessary to alleviate health or safety needs which are not reasonably satisfied by the Performer, assignee, or exclusive licensee;
or

 

(c)       Such action is
necessary to meet requirements for public use and such requirements are not reasonably satisfied by the Performer, assignee, or
exclusive licensee.

 

4.       With respect to
all Data delivered in the event of the Government’s exercise of its right under this subparagraph A.3, the Government shall
receive Unlimited Rights.

 

5.        With
respect to Data developed, generated or delivered under this Agreement, the Government shall receive Government Purpose Rights.

 

6. Any data or intellectual property developed or generated exclusively
at private expense, either prior to, or outside the scope of, this Agreement, to be utilized or delivered under this Agreement
by the Performer and/or its Subcontractors shall be delivered with restrictions as delineated in the List of Intellectual Property
Assertions provided in Attachment 5. The Performer reserves the right to add to or modify the data or intellectual property identified
in Attachment 5, but agrees that it will not use in the performance of this Agreement any private expense data or intellectual
property until Attachment 5 is modified to reflect such additional data or intellectual property, in a contractual document executed
by the Contracting Officer.

 

B.       Marking of Data

 

Pursuant to paragraph A above, any Data delivered under this
Agreement shall be marked with the following legend:

 

    	 	21 of 26	 

     

    

“Use, duplication, or disclosure is subject to the restrictions
as stated in Agreement HR0011-15-3-0001 between DARPA and Amyris, Inc.”

 

C.       Lower Tier Agreements

 

The Performer shall include this Article, suitably modified
to identify the Parties and, as applicable, Subcontractors, in all subcontracts or lower tier agreements, regardless of tier, for
experimental, developmental, or research work under the Program.

 

 

ARTICLE IX:FOREIGN ACCESS TO TECHNOLOGY

 

This Article shall remain in effect during the Term and for two (2) years thereafter.

 

A.       General

 

The Parties agree that research findings and technology developments
arising under this Agreement may constitute a significant enhancement to the national defense and to the economic vitality of the
United States. Accordingly, access to important technology developments under this Agreement by Foreign Firms or Institutions must
be carefully controlled. The controls contemplated in this Article are in addition to, and are not intended to change or supersede,
the provisions of the International Traffic in Arms Regulation (22 CFR pt. 121 et seq.), the DoD Industrial Security Regulation
(DoD 5220.22-R) and the Department of Commerce Export Regulation (15 CFR pt. 770 et seq.)

 

B.       Restrictions on Sale or Transfer
of Technology to Foreign Firms or Institutions

 

1.       In order to promote
the national security interests of the United States and to effectuate the policies that underlie the regulations cited above,
the procedures stated in subparagraphs B.2 and B.3 below shall apply to any proposed Transfer of Technology. For purposes of this
Article IX, a “Transfer of Technology” means a sale of the Performer or of a Subcontractors, and sales or licensing
of Technology, however, the term “Transfer of Technology” does not include:

 

(a)       sales of products
or components incorporating or produced via a Subject Invention(s), or licenses or sales of any genetically modified organism,
strain, or compound made by or from such an organism, strain, excluding genetically modified organism, strain or compound made
by or from an organism or strain developed under this Program.

 

(b)       licenses of software
or documentation related to sales of products or components described in clause (a), or

 

(c)       a transfer of
Technology to foreign subsidiaries of the Performer for purposes related to this Agreement or to Collaborators, or

 

(d)       a transfer of
Technology to a Foreign Firm or Institution, which is a Subcontractor or an approved source of supply or source for the conduct
of research under this Agreement; provided that such transfer shall be limited to that necessary to allow the Foreign Firm or Institution
to perform its approved role under this Agreement.

 

(e) a license and transfer of Technology solely to make,
have made, use, offer for sale, sell, or import a compound or product as, or in, a Flavor (as defined in Article VII.A.3) or Fragrance
(as defined in

Article VII.A.3).

 

    	 	22 of 26	 

     

    

2.       The Performer
shall provide written notice to the DARPA Agreements Officer’s Representative and DARPA Agreements Officer of any proposed
Transfer of Technology to a Foreign Firm or Institution by Performer or a Subcontractor at least sixty (60) calendar days prior
to the proposed date of transfer. Such notice shall cite this Article and shall state specifically what Technology is to be transferred
and the general terms of the transfer. Within thirty (30) calendar days of receipt of the Performer’s written notification,
the DARPA Agreements Officer shall advise the Performer whether it consents to the proposed Transfer. If DARPA determines that
the proposed Transfer of Technology may have adverse consequences to the national security interests of the United States, the
Performer (or, if applicable, a Subcontractor) and DARPA shall jointly endeavor to find alternatives to the proposed Transfer of
Technology which obviate or mitigate potential adverse consequences of the Transfer of Technology but which provide substantially
equivalent benefits to the Performer (or, if applicable, a Subcontractor). In cases where DARPA does not concur or sixty (60) calendar
days after receipt and DARPA provides no decision, the Performer (or, if applicable, Performer on behalf of a Subcontractor) may
utilize the procedures under Article VI, Disputes. No such Transfer shall take place until a decision is rendered.

 

3.       In the event a
Transfer of Technology to a Foreign Firm or Institution which is NOT approved by DARPA takes place, the Performer shall: (a) refund
to DARPA funds paid by DARPA for the development of such unapproved transferred Technology; and (b) the Government shall have a
non-exclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the Government such Technology
throughout the world for the Government and any and all other purposes, particularly to effectuate the intent of this Agreement.
Upon request of the Government, the Performer shall provide written confirmation of such licenses.

 

C.       Lower Tier Agreements

 

The Performer shall include this Article, suitably modified
to identify the Parties and, as applicable, Subcontractors, in all subcontracts or lower tier agreements, regardless of tier, for
experimental, developmental, or research work under the Program.

 

 

ARTICLE X: TITLE TO AND DISPOSITION OF PROPERTY

 

A.       Title to Property

 

Title to any items of Property acquired under this Agreement
with an acquisition value of $5,000 or less shall vest in the Performer (and/or its Subcontractors) upon acquisition with no further
obligation of the Parties unless otherwise determined in advance by the DARPA Agreements Officer. The Performer (and/or its Subcontractors)
will acquire Property with an acquisition value greater than $5,000 under this Agreement as set forth in Attachment 6 to this Agreement,
which Property is necessary to further the research and development goals of this Program and is not for the direct benefit of
the Government. Title to this Property shall vest in the Performer (and/or its Subcontractors) upon acquisition. Should any other
item of Property with an acquisition value greater than $5,000 be required during the Program, the Performer shall obtain prior
written approval of the DARPA Agreements Officer, which approval shall not to be unreasonably withheld or delayed. Title to this
later acquired Property shall also vest in the Performer (and/or its Subcontractors) upon acquisition. The Performer (and/or its
Subcontractors) shall be responsible for the maintenance, repair, protection, and preservation of all such Property at its own
expense.

 

B.       Disposition of Property with
Value >$5,000

 

    	 	23 of 26	 

     

    

At the completion or termination of the Term, title to (i)
items of Property set forth in Attachment 6 and (ii) any other items of Property acquired under the Program with an acquisition
value greater than $5,000 shall remain vested with the Performer and, if applicable, its Subcontractors without further obligation
to the Government.

 

 

ARTICLE XI: CIVIL RIGHTS ACT

 

This Agreement is subject to the compliance requirements of
Title VI of the Civil Rights Act of 1964 as amended (42 U.S.C. 2000-d) relating to nondiscrimination in Federally assisted programs.
The Performer has signed a Certifications for Agreement No. HR0011-15-3-0001, a copy of which is attached hereto as Attachment
7, which certifies, among other matters, the Performer’s compliance with the nondiscriminatory provisions of the Act.

 

ARTICLE XII:SECURITY

 

The Government does not anticipate the need for the Performer
(or its Subcontractors) to develop and/or handle classified information in the performance of this Agreement. No DD254 is currently
required for this Agreement.

 

ARTICLE XIII:SUBCONTRACTORS

 

The Performer shall make every effort to satisfy the intent
of competitive bidding of sub-agreements to the maximum extent practical. The Performer may use foreign entities or nationals as
Subcontractors, subject to compliance with the requirements of this Agreement and to the extent otherwise permitted by law.

 

ARTICLE XIV: KEY PERSONNEL

 

A.       The Performer shall notify the DARPA
Agreements Officer in writing prior to making any change in Key Personnel for the Program. The following individuals are designated
as ”Key Personnel” for the purposes of this Agreement:

 

	Name	Role/Title	% Time
	 	Principal Investigator (PI)	100%
	 	Co-PI	100%

 

B.       When replacing any of the Key Personnel
identified above, the Performer must demonstrate that the qualifications of the prospective Key Personnel are acceptable to the
Government as reasonably determined by the Program Manager. Substitution of Key Personnel shall be documented by modification to
the Agreement made in accordance with the procedures outlined in Article III, paragraph C.

 

 

ARTICLE XV: ORDER OF PRECEDENCE

 

In the event of any inconsistency between the terms of this
Agreement and language set forth in the Attachments, the inconsistency shall be resolved by giving precedence in the following
order: (1) the Agreement; and (2) all Attachments to the Agreement.

 

    	 	24 of 26	 

     

    

ARTICLE XVI: EXECUTION

 

This Agreement constitutes the entire agreement of the Parties
with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, understandings, negotiations
and discussions among the Parties, whether oral or written, with respect to the subject matter hereof. This Agreement may be revised
only by written consent of the Performer and the DARPA Agreements Officer. This Agreement, or modifications thereto, may be executed
in counterparts each of which shall be deemed as original, but all of which taken together shall constitute one and the same instrument.

 

 

ARTICLE XVII: APPLICABLE LAW

 

United States federal law will apply to the construction,
interpretation, and resolution of any disputes arising out of or in connection with this Agreement.

 

ARTICLE XIII: SEVERABILITY

 

In the event that any one or more of the provisions contained
herein shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability
shall not affect any other provisions of this Agreement, but this Agreement shall be construed as if such invalid, illegal or unenforceable
provisions had never been contained herein, unless the deletion of such provision or provisions would result in such a material
change so as to cause completion of the transactions contemplated herein to be unreasonable.

 

ARTICLE XIX: DATA SHARING PLAN AND STATUS REPORTING

 

It is the goal of the Government that its investment in
the tools and capabilities developed under the Program to be multiplied many-fold by adoption and improvement by researchers across
the United States. In order to achieve this vision, the Living Foundries program aims to facilitate interoperability and open the
field to new entrants.

 

The Performer shall make available the Tools developed
under the Program to the broader synthetic biology community by presenting its Program research Data at public meetings, conferences,
and workshops and publishing results in peer-reviewed journal articles. At a minimum, the types of information that will be made
available to the broader synthetic biology community are as discussed below:

 

(i) Data and analysis necessary to evaluate the utility of the Tools
developed under the Program, including standard operating procedures and design specifications enabling others to reconstitute
the equipment, set up, and approaches developed.

 

(ii) Details required for technical evaluation
of the Tools developed under the Program: full protocols, technical drawings of equipment built and specifications met, Data on
accuracy and precision of these systems, and results of procedures performed against large number of samples to investigate the
robustness and readiness of the approaches for broader distribution – providing a trained reader with the information needed
to recapitulate the methods and results described.

 

(iii) The Key Personnel shall be reasonably available
to consult with third parties seeking to replicate the results.

 

The Performer shall include as part of required monthly Technical
Status Reports in Attachment 2 an

  

    	 	25 of 26	 

     

    

on-going status of efforts to develop and/or carry out this Intellectual Property
and Data Sharing plan. Reporting shall include a summary of Data sharing activities that have taken place during the reporting
period, and any Data sharing activities planned to take place within three months of the reporting period.

 

The Performer shall also include as part of required monthly Technical Status Reports
in Attachment 2 a listing of the Performer’s Subject Invention disclosures, Subject Invention patent applications and a brief
discussion summarizing plans, if any, to license the resulting Subject Inventions (e.g., intent and rationale regarding whether
the Performer intends to seek non-exclusive licensing, exclusive licensing for a particular field of use, or exclusive licensing
across the board, etc.).

 

 

 

 

 

 

    	 	26 of 26	 

     

    

Attachment 3 – Revision 4

 

Total Agreement Funding Plan and Payable Milestones and Corresponding
Payment Schedule

 

Total Agreement Funding Plan

(for informational purposes only)

 

	 	DARPA Payment Total	Performer Contribution $	
        Agreement Funding

        Grand Total
	
        DARPA Share 

        %
	Performer Contribution %
	Module A Total	$11,267,168 	$1,238,563 	$12,505,727 	90.10%	9.90%
	Module B Total	$4,517,217 	$767,829 	$5,285,046 	85.47%	14.53%
	Module C Total	$1,065,228 	$565,813 	$1,631,041 	65.31%	34.69%
	Module D Total	$2,532,939 	$1,003,490 	$3,536,429 	71.62%	28.38%
	Module E Total	$1,183,490 	$1,939,053 	$3,122,543 	37.90%	62.10%
	Module F Total	$1,054,407 	$767,829 	$1,822,236 	57.86%	42.14%
	Module G Total	DELETED
	Module H Total	$5,895,752 	$3,831,230 	$9,726,982 	60.61%	39.39%
	Module I Total	$1,462,441 	$1,775,450 	$3,237,891 	45.17%	54.83%
	Module J Total	$3,000,887 	$2,517,831 	$5,518,718 	54.38%	45.62%
	Module K Total	$3,180,481 	$1,154,251 	$4,334,731 	73.37%	26.63%
	 	$35,160,011 	$15,561,338 	$50,721,349 	69.32%	30.68%

 

	DARPA Payment Totals by Month
	Month 3	Jan 31 2016	$1,194,797
	Month 6	Apr 30 2016	$2,763,283
	Month 9	Jul 31 2016	$852,072
	Month 12	Oct 31 2016	$6,385,002
	Month 15	Jan 31 2017	$100,567
	Month 18	Apr 30 2017	$5,379,661
	Month 21	Jul 31 2017	$350,130
	Month 24	Oct 31 2017	$5,934,327
	Month 30	Apr 30 2018	$5,262,210
	Month 33	Jul 31 2018	$119,404
	Month 36	Oct 31 2018	$3,429,005
	Month 42	Apr 30 2019	$1,974,919
	Month 42 Option	Apr 30 2019	$85,125
	Month 45	Jul 31 2019	$391,210
	Month 48	Oct 31 2019	$31,256
	Month 48 Option	Oct 31 2019	$907,043
	Baseline	 	$34,167,843
	Option	 	$992,168
	Grand Total 	 	$35,160,011

 

     

     

    

Payable Milestones and Corresponding Payment Schedule

Revision 2

 

	
        MS

        Month
	Task	Metric	
        CLIN

        Technical

        MS
	
        Payable MS

        Value
	
        Technical 

        MS

        Payment
	CLIN/SLIN/ACRN
	[*]	[*]	[*]	[*]	[*]	[*]	0001/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0002/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0003/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0004/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0005/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0006/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	0007/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0008/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0009/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0010/01/AA
	[*]	[*]	[*]	[*]	[*]

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	0011/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0013/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0016/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	0014/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0015/01/AA
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0017/01/AA
	[*]	[*]	[*]	[*]	[*]

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	0012/01/AA
	[*]	[*]	[*]	[*]	[*]	[*]	
        0019/01/AA

        0019/02/AB

	[*]	[*]	[*]	[*]	[*]	[*]	0020/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0021/02/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0022/01/AB

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	
        0023/01/AA

        0023/02/AB

	[*]	[*]	[*]	[*]	[*]	[*]	0024/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0025/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0026/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0027/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0028/01/AB

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	 	 	[*]	 	 	 	 
	[*]	[*]	[*]	[*]	[*]	[*]	0020/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0029/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0018/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0030/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0031/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0033/01/AB
	[*]	[*]	[*]	[*]	[*]

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	 	 
	[*]	[*]	[*]	[*]	[*]	[*]	0034/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0035/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0036/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0037/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0038/01/AB
	[*]	[*]	[*]	[*]	[*]

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	0039/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0032/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0040/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0041/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0042/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0043/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0044/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	0045/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0046/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0047/01/AB
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	0048/01/AB
	[*]	[*]	[*]	[*]	[*]	[*]	0049/01/AB

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	 	 	[*]	 	 	 	 
	[*]	[*]	[*]	[*]	[*]	[*]	
        0050/01/AB

        (partialy

        funded

        $431,041)

	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]
	[*]	[*]	[*]	[*]	[*]	[*]	 
	[*]	[*]	[*]	[*]	[*]	[*]	 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

	[*]	[*]	[*]	[*]	[*]	[*]	 
	 	 	Baseline Costs	 	 	$34,167,843	 
	 	 	Option Costs	 	 	$992,168	 
	 	 	TOTAL	 	 	$35,160,011	 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]